

Cycloaddition Reactions of Allenylphosphonates and Related Allenes with Dialkyl Acetylenedicarboxylates, 1,3-Diphenylisobenzofuran, and Anthracene

K. V. Sajna, Ramesh Kotikalapudi, Manab Chakravarty, N. N. Bhuvan Kumar, and K. C. Kumara Swamy*

School of Chemistry, University of Hyderabad, Hyderabad 500 046, A. P., India

kckssc@yahoo.com; kckssc@uohyd.ernet.in

Received November 10, 2010



Cycloaddition reactions of allenylphosphonates $[(RO)_2P(O)](R^1)C=C=CR^2_2]$ with dialkyl acetylenedicarboxylates, 1.3-diphenylisobenzofuran, and anthracene have been investigated and compared with those of allenoates [(EtO₂C)RC=C=CH₂] and allenylphosphine oxides [Ph₂P(O)(R¹)C=C=CR²₂] in selected cases. Allenylphosphonates $(RO)_2P(O)(Ar)C=C=CH_2$ with an α -aryl group preferentially undergo [4 + 2] cycloaddition with DMAD/DEAD under thermal activation, but in addition to the expected 1:1 (allene: DMAD) product, the reaction also leads to 1:2 as well as 2:1 products that were not reported before. When an extra vinyl group is present at the γ -carbon of allenylphosphonate [e.g., $(OCH_2CMe_2CH_2O)P(O)(Ph)C=C=CH(C=CHMe)$], [4 + 2] cycloaddition takes place utilizing either the vinylic or the aryl end, but additionally a novel cyclization wherein complete opening of the $[\beta, \gamma]$ carbon–carbon double bond of the allene is realized. In contrast to these, the reaction of allenylphosphonate $(OCH_2CMe_2CH_2O)P(O)(H)C=C=CMe_2$ possessing a terminal = CMe_2 group with DMAD occurs by both [2 + 2] cycloaddition and ene reaction. While the reaction of =CH₂ terminal allenylphosphonates as well as allenylphosphine oxides with 1,3-diphenylisobenzofuran afforded preferentially endo-[4 + 2] cycloaddition products via $[\alpha,\beta]$ attack, the analogous allenoates $[(EtO_2C)RC=C=CH_2]$ underwent exo-[4 + 2] cyclization. Under similar conditions, allenylphosphonates with a terminal = CR_2 group gave only $[\beta, \gamma]$ cycloaddition products. An unusual ring-opening of a [4 + 2] cycloaddition product followed by ringclosing via [4 + 4] cycloaddition, as revealed by ³¹P NMR spectroscopy, is reported. Anthracene reacted in a manner similar to 1,3-diphenylisobenzofuran, albeit with lower reactivity. Key products, including a set of exo- and endo- [4 + 2] cycloaddition products, have been characterized by single crystal X-ray crystallography.

Introduction

Allenes, by virtue of their reactive and cumulative double bonds, are excellent partners for both [2 + 2] and [4 + 2]cycloaddition reactions.¹ These reactions provide an atom economical approach to a diverse range of products and hence are attractive from the synthetic chemist's point of view. As an example, the [2 + 2] cycloaddition of the monosubstituted allene RCH=C=CH₂ with itself or with another partner (e.g., R'C=CR') can lead to a range of cyclobutanes/cyclobutenes, with the nature of the product depending on the electronic and/or steric requirements (Scheme 1). While the intramolecular [2 + 2] version is a valuable synthetic route to bicyclic derivatives, the corresponding intermolecular [2 + 2] cycloaddition reactions serve as efficient methods for accessing strained cyclobutane/cyclobutene rings with an additional carbon-carbon

(2) (a) Wender, P. A.; Jenkins, T. E.; Suzuki, S. J. Am. Chem. Soc. 1995, 117, 1843. (b) Ishar, M. P. S.; Kumar, K.; Kaur, S.; Kumar, S.; Girdhar, (c) Horino, Y.; Kimura, M.; Tanaka, S.; Okajima, T.; Tamaru, Y. (c) Horino, Y.; Kimura, M.; Tanaka, S.; Okajima, I.; Tamaru, Y. *Chem.—Eur. J.* 2003, *9*, 2419. (d) Alcaide, B.; Almendros, P.; Aragoncillo, C. Org. Lett. 2003, *5*, 3795. (e) Ma, S.; Gu, Z.; Deng, Y. Chem. Commun 2006, 94. (f) Jung, M. E.; Murakami, M. Org. Lett. 2006, *8*, 5857. (g) Jung, M. E.; Murakami, M. Org. Lett. 2007, *9*, 461. (h) Lohse, A. G.; Hsung, R. P. Org. Lett. 2009, *11*, 3430. (i) Jung, M. E.; Cordova, J.; Murakami, M. Org. Lett. 2009, *11*, 3882. (j) González, A. Z.; Toste, F. D. Org. Lett. 2010, *12*, 200. (3) (a) Lee, P. H.; Lee, K.; Kang, Y. J. Am. Chem. Soc. 2006, *128*, 1139. (b) Kulyk, S.; Dougherty, W. G, Jr.; Kassel, W. S.; Fleming, S. A.; Sieburth, S. M. Org. Lett. 2010, *12*, 3296

S. M. Org. Lett. 2010, 12, 3296.

(4) (a) Schneider, R.; Siegel, H.; Hopf, H. Liebigs Ann. Chem. 1981, 1812. (b) Pasto, D. J.; Kong, W. J. Org. Chem. 1989, 54, 4028. (c) Rey, J. G.; Rodríguez, J.; Lera, A. R. Tetrahedron Lett. 1993, 34, 6293. (d) Murakami, M.; Amii, H.; Itami, K.; Ito, Y. Angew. Chem., Int. Ed. **1995**, *34*, 1476. (e) López, S.; Rey, J. G.; Rodríguez, J.; Lera, A. R. Tetrahedron Lett. **1995**, 36, 4669. (f) Murakami, M.; Ashida, S.; Matsuda, T. J. Am. Chem. Soc. 2004, 126, 10838.

(5) (a) Tran, Y. S.; Kwon, O. Org. Lett. 2005, 7, 4289. (b) Tang, X.; Zhang, B.; He, Z.; Gao, R.; He, Z. Adv. Synth. Catal. 2007, 349, 2007. (c) Wallace, D. J.; Sidda, R. L.; Reamer, R. A. J. Org. Chem. 2007, 72, 1051. (d) Henry, C. E.; Kwon, O. Org. Lett. 2007, 7, 3069. (e) Panossian, A.; Fleury-Brégeot, N.; Marinetti, A. Eur. J. Org. Chem. 2008, 3826. (f) Marinetti, A.; Voituriez, A. Synlett 2010, 174.

(6) (a) Shen, Q.; Hammond, G. B. J. Am. Chem. Soc. 2002, 124, 6534. (b) Luzung, M. R.; Mauleón, P.; Toste, F. D. J. Am. Chem. Soc. 2007, 129, 12402. (c) Mauleón, P.; Zeldin, R. M; González, A. Z; Toste, F. D. J. Am. Chem. Soc. 2009, 131, 6348. (d) Alonso, I.; Trillo, B.; López, F.; Montserrat, S.; Ujaque, G.; Castedo, L.; Lledós, A.; Mascareñas, J. L. J. Am. Chem. Soc. 2009, 131, 13020. (e) Shen, R.; Zhu, S.; Huang, X. J. Org. Chem. 2009, 74, 4118. (f) Saito, N.; Tanaka, Y.; Sato, Y. Org. Lett. 2009, 11, 4124. (g) Benitez, D.; Tkatchouk, E.; Gonzalez, A. Z.; Goddard, W. A., III; Toste, F. D. Org. Lett. 2009, 11, 4798. (h) Saito, N.; Tanaka, Y.; Sato, Y. Organometallics **2009**, *28*, 669. (i) Teller, H.; Flügge, S.; Goddard, R.; Fürstner, A. *Angew. Chem., Int. Ed.* **2010**, *49*, 1949. (j) Li, W.; Yuan, W.; Shi, M.; Hernandez, E.; Li, G. Org. Lett. 2010, 12, 64.

SCHEME 1



double bond for further elaboration. Allenes can also act as dienophiles in [4 + 2] cycloadditions (Scheme 1c).² Those precursors with an additional multiple bond [e.g., eneallenes] can themselves act as dienes³ or take part in intramolecular [2 + 2] cycloadditions.⁴ Variations like phosphine catalyzed [3 + 2] cycloadditions can pave the pathway to novel five-membered heterocycles also.⁵ In addition to these, transition-metal catalyzed⁶ or microwave mediated⁷ cyclization offer opportunities for accelerating the sluggish reactions or for providing alternative pathways.

Allenylphosphonates (phosphorylated allenes) and allenylphosphine oxides constitute a class of compounds that are more readily accessible (and inexpensive) than most of the other allenes.^{8,9} An added advantage of these precursors is the use of ³¹P NMR spectroscopy in deciphering the reaction pathways; this aspect has been amply demonstrated on several occasions.^{8a,c,e} There are only a few but important reports on cycloaddition reactions involving allenylphosphonates/allenylphosphine oxides.¹⁰ In this paper, we primarily focus on the reaction of this class of compounds with DMAD [MeO₂CC=CCO₂Me], anthracene or 1,3-diphenylisobenzofuran as the second component; it may be noted that the latter two reactants act as dienes in [4 + 2] cycloadditions,

^{(1) (}a) Weinreb, S. M.; Scola, P. M. Chem. Rev. 1989, 89, 1525. (b) Nendel, M.; Tolbert, L. M.; Herring, L. E.; Islam, M. N.; Houk, K. N. J. Org. Chem. 1999, 64, 976. (c) Tsuno, T.; Yoshida, M.; Iwata, T.; Sugiyama, K. Tetrahedron 2002, 58, 7681. (d) Padwa, A.; Lipka, H.; Watterson, S. H.; Murphree, S. S. J. Org. Chem. 2003, 68, 6238. (e) Krause, N.; Hashmi, A. S. K. Modern Allene Chemistry; Wiley-VCH: Weinheim, 2004; pp 760-787. (f) Ohno, H.; Mizutani, T.; Kadoh, Y.; Miyamura, K.; Tanaka, T. Angew. Chem., Int. Ed. 2005, 44, 5113. (g) Ma, S. Chem. Rev. 2005, 105, 2829. (h) Jung, M. E.; Novack, A. R. Tetrahedron 2005, 46, 8237. (i) Alcaide, B.; Almendros, P.; Aragoncillo, C.; Redondo, M. C.; Torres, M. R. *Chem.*— *Eur. J.* **2006**, *12*, 1539. (j) Kimura, M.; Horino, Y.; Mori, M.; Tamaru, Y. *Eur. J.* **2006**, *12*, 1539. (j) Kimura, M.; Horino, Y.; Mori, M.; Tamaru, T. *Chem.—Eur. J.* **2007**, *13*, 9686. (k) Mukai, C.; Hara, Y.; Miyashita, Y.; Inagaki, F. *J. Org. Chem.* **2007**, *72*, 4454. (l) Jiang, X.; Ma, S. *Tetrahedron* **2007**, *63*, 7589. (m) Hakuba, H.; Kitagaki, S.; Mukai, C. *Tetrahedron* **2007**, *63*, 12639. (n) Hussain, I.; Yawer, M. A.; Appel, B.; Sher, M.; Mahal, A.; Villinger, A.; Fischer, C.; Langer, P. *Tetrahedron* **2008**, *64*, 8003. (o) Ogasawara, M.; Okada, A.; Nakajima, K.; Takahashi, T. Org. Lett. **2009**, *11*, 177. (p) Back, T. G.; Clary, K. N.; Gao, D. *Chem. Rev*. **2010**, *110*, 4498. (q) Alcaide, B.; Almendros, P.; Aragoncillo, C. *Chem. Soc. Rev*. **2010**, *39*, 783. (r) Croatt M. P.; Wender, P. A. *Eur. J. Org. Chem* **2010**, 19 39, 783. (r) Croatt, M. P.; Wender, P. A. Eur. J. Org. Chem. 2010, 19. (s) Henderson, J. R.; Chesterman, J. P.; Parvez, M.; Keay, B. A. J. Org. *Chem.* **2010**, *75*, 988. (1) Hayashi, R.; Feltenberger, J. B.; Hsung, R. P. Org. Lett. **2010**, *12*, 1152.

^{(7) (}a) Oh, C. H.; Gupta, A. K.; Parka, D. I.; Kimb, N. Chem. Commun. **2005**, 5670. (b) Brummond, K. M.; Chen, D. Org. *Lett.* **2005**, 7, 3473. (c) Singh, L.; Ishar, M. P. S.; Elango, M.; Subramanian, V.; Gupta, V.; Kanwal, P. J. Org. Chem. 2008, 73, 2224. (d) Ovaska, T. V.; Kyne, R. E. Tetrahedron Lett. 2008, 49, 376.

^{(8) (}a) Chakravarty, M.; Kumara Swamy, K. C. J. Org. Chem. 2006, 71, 9128. (b) Kumara Swamy, K. C.; Balaraman, E.; Satish Kumar, N. Tetrahedron 2006, 62, 10152. (c) Chakravarty, M.; Kumara Swamy, K. C. Synthesis **2007**, 3171. (d) Chakravarty, M.; Bhuvan Kumar, N. N.; Sajna, K. V.; Kumara Swamy, K. C. *Eur. J. Org. Chem.* **2008**, 4500. (e) Phani Pavan, M.; Chakravarty, M.; Kumara Swamy, K. C. Eur. J. Org. Chem. 2009, 5927. (f) Bhuvan Kumar, N. N.; Nagarjuna Reddy, M.; Kumara Swamy, K. C. (i) Dia tai analy, it. 1, and a solution of the solution of

⁽⁹⁾ Kalek, M.; Johansson, T.; Jezowska, M.; Stawinski, J. Org. Lett. 2010, 12, 4702.

^{(10) (}a) Angelov, C. M.; Mondeshka, D. M.; Tancheva, T. N. J. Chem. Soc., Chem. Commun. 1985, 647. (b) Mondeshka, D.; Tancheva, C.; Angelov, C. Chem. Ber. 1990, 123, 1381. (c) Gu, Y.; Hama, T.; Hammond, G. B. Chem. Commun. 2000, 395. (d) Scheufler, F.; Maier, M. E. Eur. J. Org. Chem. 2000, 3945. (e) Zapata, A. J.; Gu, Y.; Hammond, G. B. J. Org. Chem. 2000, 65, 227 (f) Kitagaki, S.; Okumura, Y.; Mukai, C. *Tetrahedron* 2006, *62*, 10311.
 (g) Jiang, X.; Kong, W.; Chen, J.; Ma, S. *Org. Biomol. Chem.* 2008, *6*, 3606.

CHART 1



but very limited studies are reported using allenes.^{10c,11} The current investigation is an effort to understand the nature and variety of products formed in these reactions. In addition to the [2 + 2] and [4 + 2] cycloadditions, we report a novel [4 + 4] cycloaddition as well as a new [2 + 2 + 2] cyclization reaction of an allene with DMAD (dimethyl acetylenedicarboxylate) /DEAD (diethyl acetylenedicarboxylate) wherein a C(β)=C(γ) allenic double bond is completely opened up.

Results and Discussion

The phosphorus-based allenes $1-21^{8a,d,12a,b}$ and ester allenes $22-23^{8a,12c,d}$ used in the present study are shown in Chart 1; among these, compounds 3, 6, 9 and 11–15 are new.

(i) Reaction with Dialkyl Acetylenedicarboxylates $RO_2CC \equiv CCO_2R \ [R = Me \ (DMAD), Et \ (DEAD)].$ Our initial success involved the treatment of the allenylphosphonate (OCH₂CMe₂CH₂O)P(O)(H)C=C=CMe₂ (8) with DMAD under neat condition at 150 °C/24 h, since precursors (OCH₂CMe₂CH₂O)P(O)(R¹)C=C=CH₂ [R¹ = H (1), Me (2), (*n*-Bu (3)] did not undergo any perceptible reaction. The ³¹P NMR spectrum of the reaction mixture showed

SCHEME 2



SCHEME 3



several peaks, but compounds 24-26 were the major components [total ~85%] that could be readily isolated (Scheme 2). X-ray structures have been determined for 24 and 25 (see Supporting Information). The normal rationalization for the formation of alkylidenecyclobutenes 25-26 is a stepwise diradical or a concerted [2 + 2] cycloaddition.^{1e,q,12b,13a,b} However, all three products 24-26 can also be formed via the common intermediate 27 (Scheme 3). Compound 24 can be formed^{13a,c} by H-migration from 27, and the ring closure involving γ -carbon leads to cyclobutene 26. Similarly, the rotamer 27' (of 27) affords product 25 by ring closure involving α -carbon.¹⁴ The yield of 24 could be maximized by conducting the reaction in toluene under reflux conditions. Similar products (28–29) were also obtained upon treatment of the allenes 19 and 21 with DMAD.¹⁵



Allenes (OCH₂CMe₂CH₂O)P(O)(R¹)C=C=CH₂ [R¹ = Ph (4), *p*-tolyl (5), bromophenyl (6), *p*-anisyl (7)] with a terminal =CH₂ group behaved in a manner entirely different from that of 8 (Scheme 4). The products are 30(a-c)-33-(a-c). X-ray structures have been determined for 31a and 33b (see Supporting Information). Compound 33b has



Z-stereochemistry at the terminal [-(MeO₂C)C=CH(CO₂Me)] moiety. Thus in each case, three distinct products are isolated. While formation of [4 + 2] cycloaddition compounds analogous to **30a-33a** has been reported recently by Ma and co-workers,^{10g} the other two types of [4 + 2] cycloaddition products are new. It is clear that if an additional C=C bond is present next to the α -carbon of the allene, [4 + 2] cycloaddition is the preferred reaction. With regards to products **30b-33b** and **30c-33c**, despite relatively low yields, given the consistency with which they are formed in all the four reactions, a possible rationale is provided in Scheme 4. Although the [4 + 2] cycloaddition is expected to be

(13) (a) Pasto, D. J.; Kong, W. J. Org. Chem. **1988**, 53, 4807. (b) Kitagaki, S.; Okumura, Y.; Mukai, C. Tetrahedron **2006**, 62, 10311. (c) Shibata, T.; Takesue, Y.; Kadowaki, S.; Takagi, K. Synlett **2003**, 268.

(14) Only the cyclized product was isolated in ca. 25% yield (rest: other products) from the reaction of allene (OCH₂CMe₂CH₂O)P–CH=C=CH-(Me) with DMAD [mp: 176–178 °C; IR: 1726 cm⁻¹; ¹H NMR (CDCl₃): δ 0.74 and 0.86 (2 s, 6H), 2.35 (d, J(H–H) ~2.0 Hz, 3H), 3.59–3.66 (m, 2H), 3.88 and 3.90 (2 s, 6H), 4.12 ~4.16 (m, 2H), 4.13 (d, J(P–H)=22.9 Hz, 1H), 4.16 (br, 1H). ¹³C NMR (CDCl₃): δ 17.4, 21.2, 25.5 (d, J(P-C)= 134.1 Hz, PCH), 32.3 (d, J(P–C) = 5.8 Hz), 52.7 and 52.8 (2 s), 74.9 (d, J(P–C) = 6.3 Hz), 127.9, 133.4, 133.9, 136.6, 166.8 and 167.5. ³¹P NMR: δ 20.8.].





⁽¹⁵⁾ This result may be contrasted with that of tetramethylallene $M_{2}C=C=CMe_2$ with DMAD wherein a mixture of Z and E isomers of $M_{2}C=C(C(Me)=CH_2)-C(CO_2Me)=CH(CO_2Me)$ was obtained. See: Chia, H.-A.; Kirk, B. E.; Taylor, D. R. J. Chem. Soc., Perkin Trans. I **1974**, 11, 1209.

concerted, ^{1a,b} the aromatization step is not and hence the DMAD or the allene could react further to lead to 30b-33b and 30c-33c (Scheme 5). A common intermediate in all these cases is 34.

The observation made above that [4 + 2] cycloaddition is preferred over [2 + 2] under our experimental conditions is also shown in the 1:1 reaction of cyclohexenyl substituted allene **12** with DMAD wherein the product **35** is formed quantitatively (Scheme 6). However, unlike in the case of **30a**-**33a**, aromatization of the newly formed ring did not occur.¹⁶

Perhaps more interesting is the reaction of the vinyl allenes 10-11 with DMAD/DEAD using a higher molar stoichiometry of the latter reagents (Scheme 7); in 1:1 stoichiometric reaction, some unreacted allene remained. Four compounds [36-39] were formed in each case. X-ray structures for **36a**-**b** were determined (see Supporting Information). Clearly, there was competition between the vinylic end^{10a,b,17} and any group with regards to [4 + 2] cycloaddition. The unique disubstituted products 36b-39b resulted from complete opening up of the $C(\beta) = C(\gamma)$ double bond. To our knowledge, there is no precedence for such a reaction in allene chemistry. Formation of 36a-39a, 36c-39c and 36d-39d may be rationalized by using the pathways similar to that shown in Scheme 5. In the case of 36b-39b, we believe that [2 + 2] cycloaddition happens first [cf. structure 40 in Scheme 8] followed by cyclobutene ring cleavage and subsequent addition of a second molecule o DMAD/DEAD. It may be noted that unlike compounds 25-26, wherein the cyclization site on the allene is either the $C(\alpha) = C(\beta)$ or $C(\beta) = C(\gamma)$ double bond, the formation of

^{(11) (}a) Schlindwein, H.-J.; Dichl, K.; Himbert, G. Chem. Ber. 1989, 122,
577. Chem. Abstr. 1990, 112, 55656. (b) Shakespeare, W. C.; Johnson, R. P. J. Am. Chem. Soc. 1990, 112, 8578. (c) Himbert, G.; Ruppmich, M.; Schmidt, U. Phosphorus, Sulfur Silicon Relat. Elem. 1993, 74, 387. (d) Ehm, C.; Lentz, D. Chem. Commun 2010, 2399.

^{(12) (}a) Patois, C.; Richard, L.; Savignac, P. J. Chem. Soc., Perkin Trans. I 1990, 1577. (b) Bhuvan Kumar, N. N.; Chakravarty, M.; Satish Kumar, N.; Sajna, K. V.; Kumara Swamy, K. C. J. Chem. Sci. 2009, 121, 23. (c) Guo, H.; Qian, R.; Guo, Y.; Ma, S. J. Org. Chem. 2008, 73, 7934. (d) Guo, H.; Xu, Q.; Kwon, O. J. Am. Chem. Soc. 2009, 131, 6318.

⁽¹⁶⁾ Huisgen and coworkers have reported [4 + 2] cycloaddition using styrene as the diene and 2,2-bis(trifluoromethyl)ethylene-1,1-dicarbonitrile (BTF) as the dienophile wherein aromaticity is lost in the final compound. This paper also deals with the competition between [4 + 2] and [2 + 2] cycloadditions. See: Brückner, R.; Huisgen, R.; Schmid, J. *Tetrahedron Lett.* **1990**, *31*, 7129.

^{(17) (}a) Murakami, M.; Itami, K.; Ito, Y. J. Am. Chem. Soc. 1997, 119, 7163. (b) Murakami, M.; Ubukata, M.; Itami, K.; Ito, Y. Angew. Chem., Int. Ed. 1998, 37, 2248. (c) Spino, C.; Thibault, C.; Gingras, S. J. Org. Chem. 1998, 63, 5283. (d) Hakuba, H.; Kitagaki, S.; Mukai, C. Tetrahedron 2007, 63, 12639. (e) Zhou, H.; Zhu, D.; Xie, Y.; Huang, H.; Wang, K. J. Org. Chem. 2010, 75, 2706.





36b–39b involves only the $C(\beta)=C(\gamma)$ double bond. Use of ³¹P NMR spectroscopy in conjunction with chromatography during the course of this reaction was essential to identify and separate the products.

(ii) Reaction with 1,3-Diphenylisobenzofuran. Due to the aromatization of the six-membered ring during cycloadditions, 1,3-diphenylisobenzofuran is a very reactive diene that readily undergoes [4 + 2] cycloaddition (Diels–Alder) reaction with a wide range of dienophiles.¹⁸ However, this feature has been utilized only to a very limited extent in allene chemistry.^{11b,d} Hence we explored the reaction of allenes 1–5, 7–9, 19–20 and 22–23 with 1,3-diphenylisobenzofuran (Schemes 9–10) that led to the products 41–52. Except in the cases of 8–9 and 19–20, all the allenes investigated underwent Diels–Alder reaction almost exclusively at the (α,β) carbon–carbon double bond. In the cases of 8–9 and 19–20 that have terminal alkyl groups, the cycloaddition occurred only at the (β,γ) carbon–carbon double bond.

It can be readily recognized that two configurational isomers are possible for each of 41-48 (i.e., excluding

924 J. Org. Chem. Vol. 76, No. 3, 2011

diastereomers due to chiral centers). If we consider the phosphorus substituent, these isomers can be termed as endo and exo. In the case of phosphorus compounds the presence of isomers is readily ascertained by ³¹P NMR spectroscopy $[\Delta \delta \approx +3 \text{ ppm}]$. In four cases [43a-b, 45a-b, 46a-b and 47a-b], we have been successful in isolating both these isomers. Delightedly, X-ray structures were obtained for both endo and exo p-anisyl substituted isomers 46a and 46b [see Supporting Information]. Structures of 44a, 47a and 52 were also determined to further confirm their identities. Although the endo isomer was the major product in the case of 41-46, there appeared to be a reversal in the reactions using allenoates 22-23 that lead to the products 47-48 in which the *exo*-(with respect to CO₂Et group) isomer [47b or **48b**] was the major product. The *endo* preference had been rationalized earlier by invoking secondary orbital interactions (SOIs) but a recent paper suggests that closed shell interactions are involved.¹⁹ This could explain the formation of endo-phosphonate products 41-46. An endo-selective Diels-Alder reaction of diphenyl(1,2-propadienyl)phosphine oxide with cyclopentadiene has been reported by Scheufler and Maier.^{10d} In the case of allenoate products 47a-b the ratio was \sim 2:3 in favor of *exo*, while for **48** the preferred product was again exo (i.e., 48b). The latter feature is understandable since there is a slightly bulkier germinal -CH₂CO₂Et group that could tilt the balance in favor of exo. Exo-selective [4 + 2]cycloaddition of allenoate 22 with other dienes has also been noted by Jung and co-workers recently.^{2f-i}

With respect to the X-ray structures [see Supporting Information], the nonbonded P1···O4 distance between the bridgehead oxygen and the phosphorus in the *endo* [46a] and *exo* [46b] isomers are, respectively, 3.981(3) Å and 3.328(1) Å and hence these isomers are easily distinguishable. Another

^{(18) (}a) Back, T. G.; Parvez, M.; Zhai, H. J. Org. Chem. 2006, 71, 5254.
(b) Dyke, A. M.; Gill, D. M.; Harvey, J. N.; Hester, A. J.; Lloyd-Jones, G. C.; Muñoz, M. P.; Shepperson, I. R. Angew. Chem., Int. Ed. 2008, 47, 5067.
(c) Shastin, A. V.; Nenajdenko, V. G.; Muzalevskiy, V. M.; Balenkova, E. S.; Fröhlich, R.; Haufe, G. Tetrahedron 2008, 64, 9725. (d) Quintana, I.; Peña, D.; Pérez, D.; Guitián, E. Eur. J. Org. Chem. 2009, 5519. (e) Patrick, T. B.; Li, H. J. Flourine Chem. 2009, 130, 544.

⁽¹⁹⁾ García, J. I.; Mayoral, J. A.; Salvatella, L. Eur. J. Org. Chem. 2005, 85.



SCHEME 8



interesting feature in these compounds is the unusually long C6–C7 *single* bond distances of 1.635(5) and 1.623(2) Å [see Supporting Information]. This may be because of steric repulsions involving two moderately bulky groups at C6.

It may be expected that an electron withdrawing group [e.g., phosphonyl] on the dienophile will activate this center for [4 + 2] cycloaddition, but in the reactions of allenes **8**–**9** and **19**–**20** that have a terminal = CR_2 group, the cycloaddition occurs at the (β,γ) position, away from the phosphonyl group [cf. Scheme 10]. We do not have a ready explanation for this result, but it does not appear to be a steric effect. The electronegativity of the –Me group is slightly higher than that of hydrogen according to some calculations,²⁰ but to know whether this factor tilts the reaction in favor of (β,γ) -cycloaddition or not needs further investigations.

A rather unusual [4 + 4] cycloaddition was observed in the reaction using the cyclohexenyl substituted allenes **12–15** leading to **53–56** (Scheme 11). To our knowledge, such [4 + 4] cycloadditions involving allenes are rather rare.^{3a} It is very likely that this reaction occurs via *retro* Diels–Alder reaction followed by [4 + 4] cycloaddition. Indeed, from the reaction performed at lower temperature (80 °C), [4 + 2] cycloaddi-

tion was observed, but only in the reaction using 12, we succeeded in isolating such a product (57). A pure sample of 57 upon heating at ca. 140 °C/8 h, led cleanly to the cyclooctene derivative 53 [Scheme 12] as shown by 31 P NMR spectroscopy [Figure 1]. X-ray structure of 53 was determined [see Supporting Information]. During the course of heating compound 57, the characteristic yellow color of the isobenzofuran was also observed.

(iii) Reaction with Anthracene. It is known that anthracene as a diene has low reactivity in [4 + 2] cycloaddition and to our knowledge, this diene has not been explored much in allene chemistry.^{10c,11a,c} The reaction using allenes 1-5 and 7 led to isolatable products 58-63 (Scheme 13) although it took a longer time and higher temperature than that required in the case of 1,3-diphenylisobenzofuran. The X-ray structures of 61, 64 and 66 have been determined for confirmation (see Supporting Information for details). In all these products, again the (α,β) carbon-carbon double bond preferentially acted as the dienophile. Only in the case of unsubstituted allene 1, the (β, γ) product 64 was isolated as a minor product. Allenylphosphine oxides 16–18 also afforded (α , β) cycloaddition products (65–68). In the reaction with 16, the expected product 65 was obtained along with the rearranged product 66 (ratio 1:3). Overall, these results were consistent with those obtained with 1,3-diphenylisobenzofuran discussed above.

Our initial attempt using the =CMe₂ terminal allene **8** and anthracene led only to the self-dimerized [2 + 2] cycloaddition product **69**.^{12b} Compound **2**, in addition to the Diels-Alder product **59**, also afforded **70** (Scheme 14; see Supporting Information for X-ray structure). It may be noted that this [2 + 2] addition takes place at the (β , γ)position while the Diels-Alder cycloaddition leading to **59** preferentially takes place at (α , β)-position of the allene, clearly reflecting the different electronic requirement in the two types of cycloaddition reactions.

Summary

Allenylphosphonates with an α -aryl group preferentially undergo [4 + 2] cycloaddition with DMAD/DEAD under

⁽²⁰⁾ Huheey, J. E.; Keiter, E. A.; Keiter, R. L.; Medhi, O. K. *Inorganic Chemistry: Principles of Structure and Reactivity*; Pearson Education: Boston, 2007; pp 155–170.





thermal activation, but in addition to the expected 1:1 product, the reaction leads to 1:2 as well as 2:1 products [e.g., 30-33] that were not described before. When an additional vinyl group is present in the allenylphosphonate [4 + 2] cycloaddition takes place utilizing either the vinylic [e.g., 36a-39a] or the aryl end [e.g., 36c-39c, 36d-39d], but additionally a novel cyclization product [e.g., 36b-39b], wherein complete opening up of $[\beta, \gamma]$ carbon-carbon double bond of the allene is realized. In contrast to these results, the reaction of allenylphosphonate $\mathbf{8}$ possessing a terminal = CMe₂ group with DMAD occurs by both [2 + 2] cycloaddition and ene reaction. While the reaction of =CH₂ terminal allenylphosphonates as well as allenylphosphine oxides with 1,3-diphenylisobenzofuran afforded preferentially endo-[4+2]cycloaddition products [e.g., 41a-46a] via [α , β] attack, the analogous allenoates led to exo-[4 + 2] cyclization [e.g., 47b-48b]. In contrast to both of these, under similar conditions, allenylphosphonates with a terminal $=CR_2$ group SCHEME 11



SCHEME 12



JOC Article

R¹ = Me, R² = H (2)

٠H

н

Compound 59 ÷

0

70 (X-ray)

SCHEME 13

(e)

(d)

(c)





conversion of a [4 + 2] cycloaddition product to [4 + 4]cycloaddition derivative [i.e., 57→53] was discovered. Anthracene reacted in a manner similar to 1,3-diphenylisobenzofuran, although reactivity was lower in this case. Wherever possible, rationale for the observed reactions is provided. All the key compounds were characterized by single crystal X-ray crystallography. The ready recognition of diverse products by ³¹P NMR spectra as an additional tool, that could help when analyzing reactions of nonphosphorylated allenes, is also highlighted.

69

0^

FIGURE 1. ³¹P NMR spectra showing the conversion of [4 + 2] cycloaddition compound 57 [δ (P): 23.4] to [4 + 4] cycloaddition compound **53** $[\delta(P): 13.2]$ via allene precursor **12** $[\delta(P): 8.1]$ at 140 °C in *p*-xylene: (a) after 10 min, (b) after 3 h, (c) after 5 h, (d) after 6 h, and (e) after 8 h.

gave only $[\beta, \gamma]$ -cycloaddition products [e.g., 49–52]. A new ring-opening followed by ring-closing reaction entailing

Experimental Section

General Comments. Solvents were dried according to known methods as appropriate.²¹ ¹H, ¹³C and ³¹P NMR spectra (¹H-400 MHz, ¹³C-100 MHz and ³¹P-162 MHz) were recorded using a 400 MHz spectrometer in CDCl₃ (unless stated otherwise) with shifts referenced to SiMe₄ ($\delta = 0$) or 85% H₃PO₄ ($\delta = 0$). IR spectra were recorded on an FTIR spectrophotometer. Melting points were determined by using a local hot-stage melting point apparatus and are uncorrected. Elemental analyses were carried out on a CHN analyzer. Mass spectra were recorded using GCMS or LCMS instruments.

(A) Synthesis of Allenes 1–23. The phosphorus-based allenes $1-21^{8a,d,12a,b}$ and ester allenes $22-23^{8a,12c,d}$ were synthesized according to literature procedures. Compounds 3, 6, 9, and 11-15 are new.

Compound 3. This compound was prepared by following a literature procedure^{12b} using hept-2-yn-1-ol (1.09 g, 9.7 mmol) and (OCH₂CMe₂CH₂O)PCl²² (1.63 g, 9.7 mmol). It was purified by using silica gel column chromatography [ethyl acetate/hexane (1:1)]. Isolated yield 1.80 g (76%); white solid; mp 58–60 °C; IR (KBr, cm⁻¹) 2965, 2928, 1942, 1472, 1258, 1047, 997; ¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, ³*J*(H–H) \approx 6.2 Hz, 3H), 0.95 and 1.17 (2 s, 6H), 1.32–1.37 and 1.48–1.51 (m, 4H), 2.16 (br, 2H), 3.90–4.05 (m, 4H), 4.99 and 5.02 (2 s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 21.0, 21.7, 22.1, 27.5 (d, ³*J*(P–C)=6.0 Hz), 30.0 (d, ²*J*(P–C)=6.4 Hz), 32.5 (d, ³*J*(P–C)=6.0 Hz), 76.7 (d, ³*J*(P–C)=6.5 Hz), 77.2 and 77.3 (2 d, ²*J*(P–C)=6.2 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 11.9; LC/MS *m*/*z* 245 [M + 1]⁺. Anal. calcd for C₁₂H₂₁O₃P: C, 59.00; H, 8.67. Found: C, 59.15; H, 8.59.

Compound 6. This compound was prepared by following a procedure similar to that for compound 3 using 3-(4-bromophenyl)-prop-2-yn-1-ol²³ (1.00 g, 4.7 mmol) and (OCH₂CMe₂-CH₂O)PCl (1.04 g, 4.7 mmol). It was purified by column chromatography [ethyl acetate/hexane (1:1)]. Isolated yield 1.54 g (95%); white solid; mp 78-80 °C; IR (KBr, cm^{-1}) 2984, 2961, 1964, 1931, 1485, 1264, 1154, 1053, 1003, 843, 787; ¹H NMR (400 MHz, CDCl₃) δ 0.85 and 1.26 (2 s, 6H), 3.88-3.95 (m, 4H), 5.34 and 5.37 (2 s, 2H), 7.43 (br s, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 20.6, 21.8, 32.6 (d, ³*J*(P-C) = 6.8 Hz), 77.4, 77.5, 79.4 (d, ${}^{3}J(P-C) = 14.2$ Hz), 94.6 (d, ${}^{1}J(P-C) =$ 181.3 Hz), 122.0, 129.2 (d, ${}^{3}J(P-C) = 6.0$ Hz), 129.6 (d, ${}^{2}J(P-C)$ = 7.3 Hz), 131.8, 212.6 (d, ${}^{2}J(P-C) = 3.9$ Hz); ${}^{31}P$ NMR (162) MHz, CDCl₃) δ 6.5; LC/MS m/z 342 [M]⁺ and 344 [M + 2]⁺. Anal. calcd for C₁₄H₁₆BrO₃P: C, 49.00; H, 4.70. Found: C, 49.12; H, 4.65.

Compound 9. The procedure was similar to that for **3** by using 1-ethynyl-1-cyclohexanol (2.71 g, 21.8 mmol) and (OCH₂CMe₂-CH₂O)PCl (3.68 g, 21.8 mmol). Purification was done by column chromatography [ethyl acetate/hexane (2:3)]. Isolated yield 4.71 g (85%); white solid; mp 108–112 °C; IR (KBr, cm⁻¹) 2976, 2932, 2843, 1962, 1483, 1447, 1267, 1055, 1005; ¹H NMR (400 MHz, CDCl₃) δ 0.94 and 1.19 (2 s, 6H), 1.51–1.56 (m, 2H), 1.60–1.66 (m, 4H), 2.19–2.22 (m, 4H), 3.93–4.05 (m, 4H), 5.18–5.21 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 21.8, 25.6, 26.6, 26.7, 30.0, 30.1, 32.6 (d, ³*J*(P–C) = 6.5 Hz), 76.0 (d, ¹*J*(P–C) = 193.7 Hz), 76.6₆, 76.7₁, 103.7 (d, ³*J*(P–C) = 16.5 Hz), 207.8; ³¹P NMR (162 MHz, CDCl₃) δ 10.0; LC/MS *m/z* 257 [M + 1]⁺. Anal. calcd for C₁₃H₂₁O₃P: C, 60.93; H, 8.26. Found: C, 60.85; H, 8.30.

(23) Godt, A. J. Org. Chem. 1997, 62, 7471

Compound 11. The procedure was similar to that for **3** by using 1-phenyl-4-hexen-1-yn-3- ol^{24} (0.70 g, 4.0 mmol) and (OCH₂CEt₂CH₂O)PCl (1.00 g, 4.0 mmol). It was purified by column chromatography [ethyl acetate/hexane (1:2)]. Isolated yield 1.06 g (80%); gummy; IR (neat, cm⁻¹) 2971, 1923, 1717, 1462, 1385, 1252, 1075, 1030, 845; ¹H NMR (400 MHz, CDCl₃) $\delta 0.82$ and 0.91 (2 t, ${}^{3}J(H-H) = 7.6$ and 7.4 Hz respectively, 6H), 1.12-1.28 (m, 2H), 1.76-1.84 (m, 5H), 3.97-4.13 (m, 4H), 5.88 and 6.00 (m, 2H), 6.42 (dd, ${}^{4}J(P-H) = 2.4 \text{ Hz}, {}^{3}J(H-H) \sim 9.9 \text{ Hz}$ each, 1H), 7.29–7.61 (m, 5H); 13 C NMR (100 MHz, CDCl₃) δ 6.7, 6.9, 18.1, 22.0, 22.8, 37.1 (d, ${}^{3}J(P-C) = 6.0$ Hz), 74.4 and 74.7 (2 d, ${}^{3}J(P-C) = 7.0$ Hz each), 96.8 (d, ${}^{1}J(P-C) = 181.0$ Hz), $97.4 (d, {}^{3}J(P-C) = 14.0 Hz), 122.4 (d, {}^{2}J(P-C) = 10.0 Hz), 127.4$ $(d, {}^{3}J(P-C) = 6.0 \text{ Hz}), 127.7, 128.4, 130.9 (d, {}^{3}J(P-C) = 8.0 \text{ Hz}),$ 131.9 (d, ${}^{3}J(P-C) = 5.0$ Hz); ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 7.5; $LC/MS m/z 334 [M + 2]^+$. Anal. calcd for $C_{19}H_{25}O_3P$: C, 68.66; H, 7.58 Found: C, 68.51; H, 7.62.

Compound 12. The procedure was similar to that for compound **3** by using 3-cyclohex-1-enyl-prop-2-yn-1-ol²⁵ (3.00 g, 22.0 mmol) and (OCH₂CMe₂CH₂O)PCl (3.71 g, 22.0 mmol). It was purified by column chromatography [ethyl acetate/hexane (1:1)]. Isolated yield 3.80 g (64%); white solid; mp 78–80 °C; IR (KBr, cm⁻¹) 2961, 2934, 1921, 1474, 1262, 1059, 1011; ¹H NMR (400 MHz, CDCl₃) δ 0.90 and 1.28 (2 s, 6H), 1.54–1.70 (m, 4H), 2.08 and 2.14 (2 br s, 4H), 3.99–4.01 (m, 4H), 5.18 and 5.21 (2 s, 2H), 6.29 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.8, 21.7, 21.9, 22.6, 25.9, 27.1 (d, ³*J*(P–C) = 8.1 Hz), 32.6 (d, ³*J*(P–C) = 7.1 Hz), 77.2, 77.3, 79.0 (d, ²*J*(P–C) = 14.9 Hz), 97.2 (d, ¹*J*(P–C) = 177.8 Hz), 126.7 (d, ²*J*(P–C) = 6.2 Hz), 128.9 (d, ³*J*(P–C) = 4.5 Hz), 212.1 (d, ²*J*(P–C) = 5.1 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 8.1; LC/MS *m*/*z* 269 [M + 1]⁺. Anal. calcd for C₁₄H₂₁O₃P: C, 62.67; H, 7.89. Found: C, 62.85; H, 7.82.

Compound 13. The procedure was similar to that for compound 3 by using 3-cyclohex-1-enyl-prop-2-yn-1-ol²⁵ (1.68 g, 12.3 mmol) and (OCH₂CEt₂CH₂O)PCl (2.43 g, 12.3 mmol). Purification was done by column chromatography [ethyl acetate/hexane (2:3)]. Isolated yield 2.19 g (60%); white solid; mp 80-82 °C; IR (KBr, cm⁻¹) 2940, 1929, 1464, 1260, 1080, 1034; ¹H NMR (400 MHz, CDCl₃) δ 0.76–0.80 and 0.83–0.88 (2 m, 6H), 1.18–1.22 and 1.51–1.75 (2 m, 8H), 2.04 and 2.09 (br, 4H), 3.92-4.07 (m, 4H), 5.15 and 5.18 (2 s, 2H), 6.24 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 6.9, 7.2, 21.7, 22.0, 22.6, 23.1, 25.9, 27.0 (d, ${}^{3}J(P-C) = 8.2$ Hz), 37.4 (d, ${}^{3}J(P-C) = 6.0$ Hz), 74.6, 74.7, 78.8 (d, ${}^{2}J(P-C) = 14.9$ Hz), 97.2 (d, ${}^{1}J(P-C) = 175.1$ Hz), $126.7 (d, {}^{2}J(P-C) = 6.1 Hz), 128.8, 212.0 (d, {}^{2}J(P-C) = 4.5 Hz);$ ³¹P NMR (162 MHz, CDCl₃) δ 9.1; LC/MS *m*/*z* 297 [M + 1]⁻ Anal. calcd for C₁₆H₂₅O₃P: C, 64.85; H, 8.50. Found: C, 64.72; H, 8.56.

Compound 14. The procedure was similar to that for compound **3** by using 3-cyclohexenyl-1-(phenyl)prop-2-yn-1-ol²⁶ (0.90 g, 3.5 mmol) and (OCH₂CMe₂CH₂O)PCl (0.59 g, 3.5 mmol). It was purified by column chromatography [ethyl acetate/ hexane (1:1)]. Isolated yield 0.90 g (74%); white solid; mp 108–110 °C; IR (KBr, cm⁻¹) 2948, 2917, 2830, 1919, 1599, 1456, 1260, 1061, 1013; ¹H NMR (400 MHz, CDCl₃) δ 0.75 and 1.27 (2 s, 6H), 1.59–1.67 (m, 4H), 2.04 and 2.19 (m, 4H), 3.80–4.09 (m, 4H), 6.47–6.48 (m, 1H), 6.65 (d, ⁴*J*(P–H) = 3.1 Hz, 1H), 7.25–7.28 (m, 2H), 7.32–7.37 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 20.6, 21.8, 22.0, 22.6, 26.1, 27.3 (d, ³*J*(P–C) = 8.0 Hz), 32.5 (d, ³*J*(P–C) = 7.0 Hz), 76.9 (d, ²*J*(P–C) = 6.7 Hz), 77.5 (d, ²*J*(P–C) = 174.0 Hz), 127.09, 127.11, 127.5 (d, ⁴*J*(P–C) = 6.8 Hz), 128.0 (d, ³*J*(P–C) = 1.5 Hz), 129.02, 129.03, 130.1, 132.4

⁽²¹⁾ Perrin, D. D.; Armarego, W. L. F.; Perrin, D. R. Purification of Laboratory Chemicals; Pergamon: Oxford UK, 1986.

⁽²²⁾ Kumara Swamy, K. C.; Kumaraswamy, S.; Senthil Kumar, K.; Muthiah, C. *Tetrahedron Lett.* 2005, 46, 3347.

⁽²⁴⁾ Shu, X. Z.; Liu, X. Y.; Xiao, H. Q; Ji, K. G.; Guo, L. N.; Qi, C. Z.; Liang, Y. M. Adv. Synth. Catal. 2007, 349, 2493.

⁽²⁵⁾ Dimopoulos, P.; George, J.; Tocher, D. A.; Manaviazar, S.; Hale, K. J. Org. Lett. 2005, 7, 5377.

⁽²⁶⁾ Regas, D.; Afonso, M. M.; Galindo, A.; Palenzuela, J. A. *Tetrahedron Lett.* **2000**, *41*, 6781.

(d, ${}^{2}J(P-C) = 8.2 \text{ Hz}$), 210.4 (d, ${}^{2}J(P-C) = 3.0 \text{ Hz}$); ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 6.8; LC/MS m/z 345 [M + 1]⁺. Anal. calcd for C₂₀H₂₅O₃P: C, 69.75; H, 7.32. Found: C, 69.85; H, 7.23.

Compound 15. The procedure was similar to that for compound **3** by using 3-cyclohex-1-enyl-prop-2-yn-1-ol²⁵ (0.64 g, 4.7 mmol) and (EtO)₂PCl (0.74 g, 4.7 mmol). It was purified by column chromatography [ethyl acetate/hexane (1:2)]. Isolated yield 0.79 g (65%); brown oil; IR (Neat, cm⁻¹) 2976, 2936, 1923, 1713, 1445, 1248, 1020; ¹H NMR (400 MHz, CDCl₃) δ 1.32–1.35 (m, 6H), 1.58–1.69 (m, 4H), 2.09 and 2.15 (2 br, 4H), 4.10–4.18 (m, 4H), 5.14 and 5.17 (2 s, 2H), 6.27 (br, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 16.17, 16.24, 21.8, 22.7, 26.0, 27.3 (d, ³*J*(P–C) = 8.2 Hz), 62.5₅, 62.6₁, 78.4 (d, ²*J*(P–C) = 14.7 Hz), 98.8 (d, ¹*J*(P–C) = 182.9 Hz), 127.2 (d, ²*J*(P–C) = 6.0 Hz), 128.2 (d, ³*J*(P–C) = 3.8 Hz), 213.0 (d, ²*J*(P–C) = 4.4 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 16.3; LC/MS *m/z* 257 [M + 1]⁺. Anal. calcd for C₁₃H₂₁O₃P: C, 60.93; H, 8.26. Found: C, 60.85; H, 8.21.

(B) Reaction of Allenylphosphophonates with DMAD/ DEAD. (i) Synthesis of Compounds 24-26 and 28-29. Compounds 24-26. A mixture of allenylphosphonate 8 (0.40 g, 1.80 mmol) and DMAD (0.27 g, 1.80 mmol) was heated under neat condition at 150 °C for 12 h. After this, the products 24-26 were separated by silica gel column chromatography (vide infra). Compound 24: This compound was eluted by using ethyl acetate/ hexane (2:3) mixture. Yield 85% [combined, 24+25+26, ratio 5:6:6, by ³¹P NMR], 0.14 g (isolated, 20%, **24**); mp 114–116 °C; IR (KBr, cm⁻¹) 1736, 1620, 1574, 1377, 1334, 1277, 1057, 1005; ¹H NMR (400 MHz, CDCl₃) δ 0.99 and 1.15, (2 s, 6H), 1.98 (s, 3H), 3.77 (s, 3H), 3.82-3.87 (m, 2H), 3.91 (s, 3H), 4.02-4.08 (m, 2H), 5.11 and 5.37 (2 s, 2H), 5.83 (d, J(P-H)=15.6 Hz, 1H), 6.16 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.2, 21.6, 22.2, 32.4 (d, J(P-C)=6.0 Hz), 52.2, 52.9, 76.0 (d, J(P-C)=6.0 Hz), 119.1(d, J(P-C) = 185.3 Hz), 119.8, 123.2, 139.5 (d, J(P-C) = 7.2 Hz),147.5 (d, J(PC) = 21.3 Hz), 156.6 (d, J(P-C) = 7.8 Hz), 164.9, 167.1; ³¹P NMR (162 MHz, CDCl₃) δ 9.3; GC-MS m/z 358 $[M]^+$. Anal. calcd for $C_{16}H_{23}O_7P$: C, 53.63; H, 6.47. Found: C, 53.72; H, 6.47. It was crystallized from ethyl acetate at 25 °C. Compound 25: This compound was eluted by using ethyl acetate/ hexane (3:2) mixture. Yield 85% [combined, 24+25+26, by ³¹P NMR], 0.07 g (isolated, 10%, 25); mp 180-182 °C; IR (KBr, cm⁻¹) 2953, 1732, 1698, 1595, 1435, 1265, 1061, 1009, 830, 735, 617; ¹H NMR (400 MHz, CDCl₃) δ 1.03 and 1.06 (2 s, 6H), 1.90 and 1.92 (2 s, 6H), 3.78 and 3.91 (2 s, 6H), 3.94-4.24 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 20.6, 21.3, 21.6₀, 21.6₃, 32.7 (d, ${}^{3}J(P-C) = 5.9 \text{ Hz}$, 43.3 (d, ${}^{1}J(P-C) = 145.1 \text{ Hz}$), 52.1, 52.4, 75.5, and 75.6 (2 d, ${}^{3}J(P-C) \approx 6.5$ each), 123.7 (d, ${}^{3}J(P-C) = 8.7$ Hz), 130.5 (d, ${}^{2}J(P-C) = 11.4$ Hz), 134.7, 145.8 (d, ${}^{2}J(P-C) =$ 15.9 Hz), 161.4, 162.1; ³¹P NMR (162 MHz, CDCl₃) δ 18.7; LC/ MS m/z 359 [M + 1]⁺. Anal. calcd for $C_{16}H_{23}O_7P$: C, 53.63; H, 6.47. Found: C, 53.25; H, 6.91. This compound was crystallized from ethyl acetate at 25 °C. The sample was not particularly stable in solution for more than a day. Compound 26: This compound was eluted by using ethyl acetate/hexane (1:2) mixture. Yield 85% [combined, 24+25+26, by ³¹P NMR], 0.11 g (isolated, 15%, 26); mp 166–168 °C; IR (KBr, cm⁻¹) 2961, 2930, 1742, 1723, 1669, 1437, 1260, 1059, 1009, 824; ¹H NMR (400 MHz, CDCl₃) δ 1.07 and 1.12 (2 s, 6H), 1.60 (s, 6H), 3.85 and 3.87 (2 s, 6H), 3.91 (t buried in the signals due to COOCH₃ protons, 2H), 4.19 (d \rightarrow t, ^{2,3}*J* ~ 12.0 Hz each, 2H), 6.01 (d, ²*J*(P-H) = 16.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.4, 21.5, 21.9, 32.5 (d, ${}^{3}J(P-C) = 6.0$ Hz), 52.1, 52.3, 53.4 (d, ${}^{3}J(P-C) = 10.0 \text{ Hz}), 75.4_{0}, 75.4_{4}, 103.5 \text{ (d, }{}^{1}J(P-C) = 191.0 \text{ Hz}),$ 136.0 (d, ${}^{2}J(P-C) = 27.0$ Hz), 159.0, 159.9, 161.5, 164.3 (d, ${}^{3}J(P-C) = 9.0 \text{ Hz}$); ${}^{31}P \text{ NMR}$ (162 MHz, CDCl₃) δ 10.4; LC-MS m/z 359 $[M + 1]^+$. Anal. calcd for C₁₆H₂₃O₇P: C, 53.63; H, 6.47. Found: C, 53.21; H, 6.12.

Compound 28. This compound was prepared by the above procedure from phosphorylated allene 21 (0.50 g, 1.60 mmol) and DMAD (0.23 g, 1.60 mmol); it was isolated by column chromatography using ethyl acetate/hexane (2:3) mixture as the eluent. Although the starting material was completely consumed, there were at least three other products [$\delta(P)$ 19.0, 21.6 26.1; total ~45%] in the reaction mixture. Yield 53% by ^{31}P NMR, 0.33 g (isolated, 45%); mp 128–130 °C; IR (KBr, cm⁻¹) 2970, 1744, 1719, 1613, 1370, 1335, 1264, 1020, 986, 882, 789; ¹H NMR (400 MHz, CDCl₃) δ 1.19 and 1.26 (2 d, $J \approx 6.7$ Hz for each, (12H + 12H = 24H)), 2.05 (s, 3H), 3.51-3.59 (m, 4H), 3.74 and 3.89 (2s, 6H), 4.82 (s, 1H), 5.30 (m, J ~ 1.6 Hz, 1H), 5.88 (d, $^{2}J(P-H) = 12.4$ Hz, 1H), 6.19 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 23.1, 23.4, 45.7 (d, ²*J*(P–C) = 4.8 Hz), 52.1, 52.6, 117.2, 120.6, 128.6 (d, ${}^{1}J(P-C) = 144.3$ Hz), 140.0 (d, ${}^{3}J(P-C) =$ 5.2 Hz), 148.0 (d, ${}^{3}J(P-C) = 7.3$ Hz), 149.8 (d, ${}^{2}J(P-C) = 21.6$ Hz), 165.7, 168.3; ³¹P NMR (162 MHz, CDCl₃) δ 17.9; LC/MS m/z456 [M]⁺. Anal. calcd for C₂₃H₄₁N₂O₅P: C 60.51; H 9.05; N 6.14. Found: C 60.25; H 8.89; N 6.12.

Compound 29. This compound was prepared by the above procedure from allenylphosphine oxide 19 (0.50 g, 1.87 mmol) and DMAD (0.26 g, 1.87 mmol). The ³¹P NMR spectrum of the reaction mixture at this stage showed compound 29 (ca. 60%) along with other minor products [δ (P) 7.8, 26.2, 28.1, 45.2]. The reaction mixture was chromatographed by using ethyl acetate/ hexane (2:3) mixture as the eluent to obtain compound 29 in a pure state. Yield ~60% by ³¹P NMR, 0.34 g (isolated, 44%); mp 110–112 °C; IR (KBr, cm⁻¹) 3058, 2961, 1730, 1617, 1435, 1262, 1102, 1017, 797, 696; ¹H NMR (400 MHz, CDCl₃) δ 1.72 (s, 3H), 3.76 and 3.88 (2 s, 6H), 4.86 and 5.11 (2 s, 2H), 6.10 (s, 1H), 6.43 $(d, {}^{2}J(P-H) = 19.2 \text{ Hz}, 1\text{H}), 7.44 - 7.73 \text{ (m, 10H)}; {}^{13}C \text{ NMR} (100)$ MHz, CDCl₃) δ 22.3, 52.3, 52.9, 120.5, 122.4, 126.6 (d, J(P-C) =100.0 Hz), 128.4 (d, ${}^{2}J(P-C) =$ 16.0 Hz), 131.1 (d, ${}^{3}J(P-C) =$ 10.0 Hz), 131.8, 133.8 (d, ${}^{1}J(P-C) =$ 106.0 Hz), 139.0 (d, ${}^{3}J(P-C) =$ 6.3 Hz), 147.3 (d, ${}^{2}J(P-C) = 18.1$ Hz), 156.3, 165.1, 167.5; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 17.9; LC/MS m/z 411 [M + 1]⁺. Anal. calcd for C₂₃H₂₃O₅P: C 67.31; H 5.65. Found: C 66.85; H 5.63.

(ii) Synthesis of Compounds 30(a-c)-33(a-c), 35, and 36-(a-d)-39(a-d). Compounds 30(a-c). A mixture of allenylphosphonate 4 (0.80 g, 3.03 mmol) and DMAD (1.29 g, 9.08 mmol) [1:3 ratio] in *p*-xylene (6 mL) was heated under reflux for 12 h. The solvent was removed in vacuo using a rotary evaporator. After this, the products 30a-c were separated by using silica gel column chromatography (vide infra). Compound 30a eluted first followed by 30b and then 30c. Compound 30a: It was separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield 80% [combined, 30a+30b+30c, ratio 4:1:3, by ³¹P NMR], 0.43 g (isolated, 35%, **30a**); white solid; mp 120-122 °C; IR (KBr, cm⁻¹) 2955, 2886, 1736, 1439, 1343, 1252, 1202, 1156, 1059, 1009, 830, 816, 785; ¹H NMR (400 MHz, $CDCl_3$) δ 0.72 and 1.37 (2 s, 6H), 2.78 (d, ${}^4J(P-H) = 2.0$ Hz, 3H), 3.61-3.58 (m, 2H), 3.91-4.01 (m, 2H), 3.96 and 4.03 (2 s, 6H), 7.59-8.70 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 20.3, 20.6 (d, ${}^{3}J(P-C) = 5.1 \text{ Hz}$, 22.1, 32.1 (d, ${}^{3}J(P-C) = 5.7 \text{ Hz}$), 52.9, 53.1, 76.6₀, 76.6₃, 125.3, 126.2, 126.3 (d, ${}^{3}J(P-C) = 4.3$ Hz), 127.5, 127.8 (d, ${}^{2}J(P-C) = 12.7$ Hz), 128.9, 132.5 (d, ${}^{2}J(P-C) = 17.2$ Hz), 133.9 (d, ${}^{3}J(P-C) = 5.4$ Hz), 134.0 (d, ${}^{4}J(P-C) = 2.8$ Hz), $138.9 (d, {}^{3}J(P-C) = 11.0 Hz), 167.7, 168.2; {}^{31}P NMR (162 MHz), 167.7, 168.2; {}^{31}P NMR (162 M$ CDCl₃) 10.8; LC/MS m/z 407 [M + 1]⁺. Anal. calcd for C₂₀H₂₃O₇P: C 59.11; H 5.70. Found: C 58.91, H 5.75. Compound 30b: It was separated by using ethyl acetate/hexane (3:2) mixture as the eluent Yield [30a+30b+30c] 80% by ³¹P NMR, 0.12 g (isolated, 7%, 30b); white solid; mp 124-126 °C; IR (KBr, cm⁻¹) 2955, 1744, 1732, 1651, 1435, 1373, 1150, 1059, 918, 828, 783; ¹H NMR (400 MHz, CDCl₃) δ 0.84 and 1.20 (2 s, 6H), 3.67 $(s, 3H), 3.75 (t, 2H, {}^{3}J(H-H) = 10.4 Hz), 3.85, 3.90, and 4.02 (3 s, 3.90)$ 9H), 4.20 (t, 2H, ${}^{3}J(H-H) = 10.2$ Hz), 4.48 (s, 2H), 5.41 (s, 1H),

7.66-8.81 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 21.7, 32.4 (d, ${}^{3}J(P-C) = 5.0$ Hz), 36.4, 51.9, 52.7, 53.2, 76.8, 122.4, 126.4, 127.1, 128.3, 128.7 (d, ${}^{2}J(P-C) = 13.0$ Hz), 129.3, 130.0, 131.4 (d, ${}^{2}J(P-C) = 17.0$ Hz), 134.0 (d, ${}^{3}J(P-C) = 18.5$ Hz), 135.4, 135.6, 135.7, 146.8, 165.6, 167.6, 167.7, 167.8; ³¹P NMR $(162 \text{ MHz}, \text{CDCl}_3) \delta 10.8; \text{LC/MS} m/z 549 [M + 1]^+$. Anal. calcd for C₂₆H₂₉O₁₁P: C 56.94; H 5.33. Found: C 57.21; H 5.35. **Compound 30c:** It was separated by using ethyl acetate/hexane (4:1) mixture as the eluent. Yield [30a+30b+30c] 80% by ³¹P NMR, 0.47 g (isolated, 23%, 30c); white solid; mp 160-162 °C; ¹) 2955, 1734, 1644, 1543, 1456, 1260, 1059, 1009, IR (KBr, cm⁻ 828, 781, 519; ¹H NMR (400 MHz, CDCl₃) δ 0.67, 0.82, 1.10, and 1.28 (4 s, 12H), 3.50–4.07 (m, 15H), 4.27 (s, 2H), 4.89 and 5.92 (2 s, 2H), 5.92 (s, 1H), 7.12–8.74 (m, 9H); 13 C NMR (100 MHz, CDCl₃) δ 20.5, 20.8, 21.9, 22.0, 32.2, and 32.5 (2 d, ³*J*(P-C)= 5.0 and 7.0 Hz respectively), 40.9 (d, ${}^{3}J(P-C) = 11.0$ Hz), 47.2 (d, ${}^{1}J(P-C) = 125.0 \text{ Hz}$, 52.7, 53.0, 76.3, and 76.4 (2 d, ${}^{3}J(P-C) =$ 7.0 Hz each, OCH₂), 117.2, 126.3, 126.6, 126.9, 127.4, 127.8, 128.2, 128.4, 128.6, 129.0, 129.5 (d, ${}^{3}J(P-C) = 7.0$ Hz), 131.6 (d, $^{2}J(P-C) = 17.0 \text{ Hz}$, 133.9, 134.0, 135.1, 139.6 (d, $^{2}J(P-C) = 11.0 \text{ Hz}$), 142.0, 167.6, 167.7; ³¹P NMR (162 MHz, CDCl₃) δ 10.8 and 17.8; LC/MS m/z 670 [M]⁺. Anal. calcd for C₃₄H₄₀O₁₀P₂: C 60.89; H 6.01. Found: C 60.75; H 6.11.

Compounds 31(a-c). These compounds were prepared by a procedure similar to that for 30a-c using allenylphosphonate 5 (1.00 g, 3.6 mmol) and DMAD (1.60 g, 10.8 mmol). Compound 31a: This compound was separated by using ethyl acetate/ hexane (2:3) mixture as the eluent. Yield 97% [combined, 31a+31b+31c, ratio 15:2:3, by ³¹P NMR], 1.02 g (isolated, 67%, **31a**); white solid; mp 122–124 °C; IR (KBr, cm⁻¹) 2957, 2919, 1732, 1568, 1505, 1441, 1061, 1009, 945, 916, 835, 785; ¹H NMR (400 MHz, CDCl₃) δ 0.71 and 1.37 (2 s, 6H), 2.52 (s, 3H), $2.75 (d, {}^{4}J(P-H) = 2.0 Hz, 3H), 3.58-3.60 (m, 2H), 3.89-3.98$ (m, 2H), 3.96 and 4.03 (2 s, 6H), 7.46–8.58 (m, 3H); $^{13}\mathrm{C}$ NMR $(100 \text{ MHz}, \text{CDCl}_3) \delta 20.2, 20.3 \text{ (d, }^{3}J(P-C) = 4.8 \text{ Hz}), 21.5, 22.0,$ $31.9 (d, {}^{3}J(P-C) = 5.5 Hz), 52.7, 52.9, 76.5_{0}, 76.5_{3}, 124.9, 125.7$ $(d, {}^{1}J(P-C) = 171.0 \text{ Hz}), 125.9 (d, {}^{3}J(P-C) = 4.0 \text{ Hz}), 128.0 (d,$ $^{2}J(P-C) = 12.7 \text{ Hz}$, 131.1, 132.2, 132.3 (d, $^{2}J(P-C) = 28.7 \text{ Hz}$), 133.3, 137.5, 137.7 (d, ${}^{2}J(P-C) = 11.0$ Hz), 167.7, 168.2; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 11.4; LC/MS m/z 421 [M + 1]⁺. Anal. calcd for C₂₁H₂₅O₇P: C 60.00; H 5.99. Found: C 60.21; H 5.88. This compound was crystallized from toluene/ethyl acetate (1:4) mixture at 25 °C. Compound 31b: This compound was separated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield [31a+31b+31c] 97% by ³¹P NMR, 0.12 g (isolated, 6%, **31b**); white solid; mp 132-134 °C; IR (KBr, cm⁻¹) 2953, 1741, 1437, 1362, 1267, 1055, 1007, 831, 785, 529; ¹H NMR (400 MHz, CDCl₃) δ 0.82 and 1.20 (2 s, 6H), 2.54 (s, 3H), 3.66 (s, 3H), M112, CDC(3) 0 0.02 and 120 (2.0, 0.1), 20 (.0, 0.1), 21 (.0, 0.1), 3.73 (dd \rightarrow t, ^{2,3} $J \sim$ 11.0 Hz each, 2H), 3.84, 3.89, and 4.00 (3 s, 9 H), 4.18 (dd \rightarrow t, ^{2,3} $J \sim$ 11.0 Hz each, 2H), 4.46 (s, 2H), 5.41 (s, 1H), 7.52–8.70 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1, 21.8, 32.4, 36.4, 51.9, 52.7, 53.2, 76.8, 122.3, 125.2, 126.9, 128.8 $(d, {}^{1}J(P-C) = 174.8 \text{ Hz}), 129.0 (d, {}^{2}J(P-C) = 13.8 \text{ Hz}), 131.3,$ 131.6, 132.4 (d, ${}^{2}J(P-C) = 10.3 \text{ Hz}$), 134.6 (d, ${}^{3}J(P-C) = 8.5 \text{ Hz}$), 134.9, 138.6, 147.0, 165.7 167.8; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 11.1; LC/MS m/z 563 [M + 1]⁺. Anal. calcd for C₂₇H₃₁O₁₁P: C 57.65; H 5.55. Found: C 57.48; H 5.65. Compound 31c: This compound was separated by using ethyl acetate/hexane (4:1) mixture as the eluent. Yield [31a+31b+31c] 97% by ³¹P NMR, 0.25 g (isolated, 10%, 31c); white solid; mp 164-166 °C; IR (KBr, cm⁻¹) 2957, 2892, 1732, 1724, 1644, 1437, 1256, 1059, 1009, 828, 783, 530; ¹H NMR (400 MHz, CDCl₃) δ 0.65, 0.84, 1.10, and 1.28 (4 s, 12H), 2.23 and 2.25 (2 s, 6H), 3.49-4.03 (m, 5H), 4.24 (s, 2H), 4.87 and 5.89 (2 s, 2H), 6.89–8.62 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 20.7, 20.9, 21.5, 21.8, 21.9, 32.0, and 32.4 (2 d, ${}^{3}J(P-C) = 6.0$ Hz each), 40.7 (d, ${}^{3}J(P-C) =$ 9.0 Hz), 46.4 (d, ${}^{1}J(P-C) = 129.0$ Hz), 52.5, 52.8, 76.2, and 76.3 $(2 d, {}^{3}J(P-C) = 7.0 and 6.0 Hz respectively), 116.9, 124.9, 126.2,$

126.3, 128.0, 128.4, 128.5, 128.7, 129.1 (d, ${}^{3}J(P-C) = 6.0$ Hz), 130.6 (d, ${}^{3}J(P-C) = 7.0$ Hz), 131.2, 131.4 (d, ${}^{2}J(P-C) = 18.0$ Hz), 132.2 (d, ${}^{2}J(P-C) = 12.0$ Hz), 134.4, 136.8, 137.8, 138.5 (d, ${}^{2}J(P-C) = 11.0$ Hz), 142.1, 167.6, 167.7; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 10.8 and 17.8; LC/MS *m/z* 700 [M + 2]⁺; Anal. calcd for C₃₆H₄₄O₁₀P₂: C 61.89; H 6.35. Found: C 61.75; H 6.41.

Compounds 32(a-c). These compounds were prepared by a procedure similar to that for 30a-c using allenylphosphonate 6 (0.50 g, 1.46 mmol) and DMAD (0.62 g, 4.38 mmol). Compound 32a: It was separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield 95% [combined, 32a+32b+32c, ratio 12:2:5, by ³¹P NMR], 0.39 g (isolated, 55%, **32a**); white solid; mp 136–138 °C; IR (KBr, cm⁻¹) 2959, 2878, 1732, 1435, 1273, 1055, 1011, 821, 523; ¹H NMR (400 MHz, CDCl₃) δ 0.74 and 1.36 (2 s, 6H), 2.75 (s, 3H), 3.59-3.90 (m, 4H), 3.96 and 4.03 (2 s, 6H), 7.69-8.58 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 20.6 (d, ${}^{3}J(P-C) = 4.6 \text{ Hz}$, 22.0, 32.1 (d, ${}^{3}J(P-C) = 5.5 \text{ Hz}$), 53.0, 53.3, 76.7, 122.2, 126.8 (d, ${}^{1}J(P-C) = 172.1 \text{ Hz}$), 128.0 (d, ${}^{3}J(P-C) =$ 3.8 Hz), 128.3, 129.2 (d, ${}^{2}J(P-C) = 12.6$ Hz), 132.2, 132.3, 132.5, 133.9 (d, ${}^{2}J(P-C) = 16.8$ Hz), 139.2 (d, ${}^{3}J(P-C) = 10.8$ Hz), 167.0, 168.0; ³¹P NMR (162 MHz, CDCl₃) 10.1; LC/MS m/z 485 $[M + 1]^+$, 487 $[M + 3]^+$. Anal. calcd for C₂₀H₂₂BrO₇P: C 49.50; H 4.57. Found: C 49.61; H 4.48. Compound 32b: It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield [32a+32b+32c] 95% by ³¹P NMR, 0.06 g (isolated, 6%, **32b**); white solid; mp 144–146 °C; IR (KBr, cm⁻¹) 2955, 1732, 1651, 1437, 1256, 1057, 1013, 830 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 0.84 and 1.17 (2 s, 6H), 3.65 (s, 3H), 3.72−3.78 (m, 2H), 3.83, 3.88, and 4.00 (3 s, 9H), 4.18 (dd→t, 2H, ^{2,3}*J* = 12.0 Hz), 4.43 (s, 2H), 5.37 (s, H), 7.73−8.68 (m, 4H); ¹³C NMR (100 MHz, ²) $CDCl_3$) δ 21.2, 21.6, 32.5 (d, ${}^{3}J(P-C) = 6.0$ Hz), 36.4 (d, ${}^{3}J(P-C) =$ 3.7 Hz), 52.0, 52.7, 53.3, 53.4, 76.8, and 76.9 (2s, OCH₂), 122.6, 123.2, 128.4, 128.9 (d, ${}^{3}J(P-C) = 3.5$ Hz), 129.9 (d, $^{2}J(P-C) = 12.5 \text{ Hz}), 132.4, 132.5, 132.8 (d, {}^{2}J(P-C) = 16.9 \text{ Hz}), 132.4, 132.5, 132.8 (d, {}^{2}J(P-C) = 16.9 \text{ Hz}), 134.0, 135.9 (d, {}^{3}J(P-C) = 10.9 \text{ Hz}), 146.4, 165.5, 166.9,$ 167.3, 167.7; ³¹P NMR (162 MHz, CDCl₃) δ 10.1; LC/MS *m*/*z* 627 $[M + 1]^+$, 629 $[M + 3]^+$. Anal. calcd for $C_{26}H_{28}BrO_{11}P$: C 49.78; H 4.50. Found: C 49.62; H 4.58. Compound 32c: It was separated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield [**32a+32b+32c**] 95% by ³¹P NMR, 0.22 g (isolated, 18%, **32c**); pale yellow solid; mp 168–170 °C; IR (KBr, cm⁻ 2957, 2888, 1736, 1721, 1641, 1576, 1476, 1256, 1067, 828, 785, 741, 687; ¹H NMR (400 MHz, CDCl₃) δ 0.70, 0.88, 1.12, and 1.33 (4 s, 12H), 3.46–4.15 (m, 15H), 4.31 (s, 2H), 5.06 and 5.91 (2 s, 2H), 6.97-8.59 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 20.4, 20.7, 21.9, 22.0, 32.1, and 32.5 (2 d ${}^{3}J(P-C) = 5.4$ and 6.3 Hz respectively), 41.4 (d, ${}^{3}J(P-C) = 8.3$ Hz), 45.2 (d, ${}^{1}J(P-C) =$ 113.0 Hz), 52.8, 53.2, 76.3, and 76.5 (2 d, ${}^{3}J(P-C) = 6.5$ and 5.8 Hz), 118.6, 121.2, 122.7, 126.8, 127.9 (d, ${}^{3}J(P-C) = 2.7$ Hz), 128.4, $129.4 (d, {}^{2}J(P-C) = 13.0 Hz), 130.7, 132.3, 132.4, 132.6, 132.8,$ 134.1, 140.1 (d, ${}^{2}J(P-C) = 11.5$ Hz), 141.0, 167.0, 167.1; 31 P NMR (162 MHz, CDCl₃) δ 10.2 and 17.3; LC/MS m/z 827 $[M+1]^+$, 829 $[M+3]^+$, 831 $[M+5]^+$. Anal. calcd for $C_{34}H_{38}$ -Br₂O₁₀P₂: C 49.29; H 4.62. Found: 49.38; H 4.56.

Compounds 33(a–c). These compounds were prepared by a procedure similar to that for **30a–c** using allenylphosphonate **7** (0.40 g, 1.36 mmol) and DMAD (0.58 g, 4.08 mmol). **Compound 33a:** It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield 98% [combined, **33a+33b+33c**, ratio 12:3:5, by ³¹P NMR], 0.30 g (isolated, 50%, **33a**); white solid; mp 148–150 °C; IR (KBr, cm⁻¹) 2955, 2882, 1732, 1624, 1507, 1435, 1227, 1150, 1059, 1005, 912, 830, 783, 527; ¹H NMR (400 MHz, CDCl₃) δ 0.71 and 1.36 (2 s, 6H), 2.72 (d, ⁴J(P–H)=2.0 Hz, 3H), 3.58–3.61 (m, 2H), 3.90–4.01 (m, 11H), 7.27–8.60 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 20.2 (d, ³J(P–C) = 5.0 Hz), 20.3, 22.1, 32.0 (d, ³J(P–C) = 5.0 Hz), 52.8, 53.0, 55.3, 76.6_0, 76.6_1, 104.4, 121.3, 126.2 (d, ¹J(P–C) = 170.6 Hz), 127.8 (d, ³J(P–C) = 4.1 Hz), 129.4, 129.6, 129.7, 129.8, 131.9, 133.5

(d, ${}^{2}J(P-C) = 17.1$ Hz), 135.8 (d, ${}^{2}J(P-C) = 10.8$ Hz), 158.4, 167.7, 168.5; ³¹P NMR (162 MHz, CDCl₃) 11.3; LC/MS m/z 437 $[M + 1]^+$. Anal. calcd for $C_{21}H_{25}O_8P$: C 57.80; H 5.77. Found: C 57.68; H 5.86. Compound 33b: It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield [33a+33b+33c]98% by ³¹P NMR, 0.06 g (isolated, 8%, **33b**); white solid; mp 158–160 °C; IR (KBr, cm⁻¹) 2957, 1740, 1622, 1507, 1437, 1377, 1264, 1169, 1057, 1009, 830, 511; ¹H NMR (400 MHz, CDCl₃) δ 0.83 and 1.20 (2 s, 6H), 3.67 (s, 3H), 3.74 (dd \rightarrow t, ^{2,3}*J* = 12.0 Hz, 2H), 3.85, 3.89, 3.94, and 4.00 (4 s, 12H), 4.16 (dd \rightarrow t, ^{2,3}J= 12.0 Hz, 2H), 4.42 (s, 2H), 5.40 (s, 1H), 7.32–8.72 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 21.1 and 21.7, 32.4 (d, ${}^{3}J(P-C) = 5.6$ Hz), 36.2, 51.9, 52.6, 53.1, 55.5, 76.8, 104.4, 121.7, 122.2, 128.7, 129.6 $(d, {}^{2}J(P-C) = 11.9 \text{ Hz}), 129.9, 130.7 (d, {}^{2}J(P-C) = 14.7 \text{ Hz}),$ 132.4, 132.5, 132.6, 133.5, 147.1, 159.0, 165.6, 167.7, 167.9; ³¹P NMR (162 MHz, CDCl₃) δ 11.3; LC/MS *m*/*z* 578 [M]⁺. Anal. calcd for C₂₇H₃₁O₁₂P: C 56.06; H 5.40 Found: C 56.18; H 5.35. This compound was crystallized from ethyl acetate/dichloromethane (1:2) mixture at 25 °C. Compound 33c: It was separated by using ethyl acetate/hexane (4:1) mixture as the eluent. Yield [**33a**+**33b**+**33c**] 98% by ³¹P NMR, 0.23 g (isolated, 23%, **33c**); white solid; mp 170–172 °C; IR (KBr, cm⁻¹) 2968, 1740, 1620, 1510, 1264, 1009, 828; ¹H NMR (400 MHz, CDCl₃) δ 0.67, 0.85, 1.11, and 1.31 (4 s, 12H), 3.49–4.05 (m, 21H), 4.23 (s, 2H), 4.91 and 5.87 (2 s, 2H), 6.59–8.65 (m, 7H); ¹³C NMR (100 MHz, $CDCl_3$) δ 20.3, 20.7, 21.8, 22.0, 32.0, and 32.4 (2 d ³J(P-C)=5.0 and 6.4 Hz respectively), 40.7, 45.5 (d, ${}^{1}J(P-C) = 123.2$ Hz), 52.6, 53.8, 55.0, 55.3, 76.2, and 76.3 (2 d, ${}^{3}J(P-C) = 6.9$ and 6.4 Hz respectively), 104.2, 113.3, 117.0 (d, ${}^{3}J(P-C) = 4.0$ Hz), 121.3, 125.2, 125.5 (d, ${}^{3}J(P-C) = 5.2$ Hz), 127.9, 128.1, 129.0, 129.4 (d, ${}^{2}J(P-C) = 11.6$ Hz), 130.0, 130.1, 130.2 (d, ${}^{3}J(P-C) = 4.6$ Hz), 132.4 (d, ${}^{2}J(P-C) = 16.7$ Hz), 133.2, 136.7 (d, ${}^{2}J(P-C) = 10.4$ Hz), 142.1, 158.5, 158.7, 167.7; ³¹P NMR (162 MHz, CDCl₃) δ 10.7 and 17.9; LC/MS m/z 731 [M + 1]⁺. Anal. calcd for C₃₆H₄₄O₁₂P₂: C 59.18; H 6.07. Found: C 59.32; H 5.95.

Compound 35. This compound was prepared by using above procedure, but the molar ratio of allene:DMAD was 1:1. Treatment of allenylphosphonate 12 (0.30 g, 1.11 mmol) and DMAD (0.16 g, 1.11 mmol) resulted in compound 35. It was purified by using silica gel column chromatography [ethyl acetate/hexane (2:3)]. Yield quantitative by ³¹P NMR, 0.39 g (isolated, 85%); gummy solid; IR (neat, cm⁻¹) 2953, 1734, 1640, 1437, 1269, 1059, 1009; ¹H NMR (400 MHz, CDCl₃) δ 0.84 and 1.32 (2 s, 6H), 1.58-1.66 and 1.84-1.87 (2 m, 3H), 2.07-2.28 (m, 3H), 3.33-3.47 (m, 2H), 3.72-3.78 (m, 2H), 3.81-3.93 (m, 9H), 5.36 and 5.90 (2 br, 2H); 13 C NMR (100 MHz, CDCl₃) δ 20.7, 22.2, 26.2, 29.9, 32.2 (d, ${}^{3}J(P-C) = 5.7$ Hz), 34.2 (d, J(P-C) = 5.7 Hz) 6.5 Hz), 36.6, 44.1 (d, J(P-C) = 14.7 Hz), 52.5, 52.7, 76.4 (d, $^{2}J(P-C) = 6.3$ Hz), 76.6 (d, $^{2}J(P-C) = 6.5$ Hz), 116.9 (d, $^{1}J(P-C) = 6.5$ (d, $^{1}J(P-C)$ 172.6 Hz), 119.2, 128.5, 133.1 (d, J(P-C) = 15.9 Hz), 140.5 (d, J(P-C) = 10.8 Hz), 160.6 (d, J = 8.6 Hz), 165.5, 168.4; ³¹P NMR (162 MHz, CDCl₃) δ 11.0; LC/MS m/z 411 [M + 1]⁺. Anal. calcd for C₂₀H₂₇O₇P: C, 58.53; H, 6.63. Found: C, 58.45; H, 6.69.

Compounds 36(a–d). These compounds were prepared by a procedure similar to that for **30a–c** using allenylphosphonate **10** (0.7 g, 2.3 mmol) and DMAD (0.81 g, 6.9 mmol). Isomers **36(c,d)** eluted first followed by **36a** and then **36b**. **Compound 36a:** It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield quantitative [**36a+36b+36(c,d)**, ratio 3:2:5 by ³¹P NMR], 0.24 g (isolated, 28%, **36a**); mp 134–136 °C; IR (KBr, cm⁻¹) 2953, 2882, 1732, 1715, 1601, 1435, 1406, 1373, 1161, 1109, 1057, 833, 787, 700; ¹H NMR (400 MHz, CDCl₃) δ 0.89 and 1.06 (2 s, 6H), 2.38 (s, 3H), 3.79 and 3.85 (2 s, 6H), 3.88–4.13 (m, 4H), 5.44 (d, ²*J*(P–H) = 24.0 Hz, 1H), 7.22–8.00 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 19.9, 21.6, 32.5 (d, ³*J*(P–C)=6.0 Hz), 43.1 (d, ¹*J*(P–C) = 134.0 Hz), 52.4, 52.6, 76.0 (d, ²*J*(P–C) = 7.0 Hz), 76.2 (d, ²*J*(P–C) = 6.0 Hz), 127.5, 128.7, 129.6 (d, ²*J*(P–C) = 8.0 Hz), 131.9 (d, ²*J*(P–C) = 11.0 Hz), 132.3 (d,

 ${}^{3}J(P-C) = 5.0$ Hz), 132.5, 133.0 (d, ${}^{3}J(P-C) = 3.0$ Hz), 133.1, 135.7 (d, ${}^{3}J(P-C) = 6.0$ Hz), 136.1, 168.5, 168.6; ${}^{31}P$ NMR (162) MHz, CDCl₃) δ 19.0; LC/MS m/z 447 [M + 1]⁺. Anal. calcd for C23H27O7P: C 61.88; H 6.10. Found: C 61.68; H 6.02. This compound was crystallized from ethyl acetate/hexane (4:1) mixture at 25 °C. Compound 36b: It was separated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative [36a+36b+36(c,d)] by ³¹P NMR, 0.19 g (isolated, 14%, **36b**); mp 126–128 °C; IR (KBr, cm⁻¹) 2953, 1732, 1439, 1314, 1254, 1204, 1059, 1007, 824, 696, 534; ¹H NMR (400 MHz, CDCl₃) δ 0.87 and 0.99 (2 s, 6H), 1.83 (d, ³*J*(H–H) = 6.4 Hz, 3H), 3.64 (s, 6H), 3.67–3.88 (m, 2H), 3.80 (s, 3H), 4.13–4.21 (m, 2H), 5.78–5.85 (m, 2H), 6.43 (d, ${}^{2}J(P-H) = 16.0$ Hz, 1H), 7.22-7.47 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 19.0, 21.4, 21.6, 32.6 (d, ${}^{3}J(P-C) = 7.0$ Hz), 44.6 (d, ${}^{1}J(P-C) = 139.0$ Hz), (d, ${}^{2}J(P-C) = 10.0 \text{ Hz}$), $41.6 \text{ (d}, {}^{2}J(P-C) = 102.6 \text{ Hz}$), 52.7, 52.8, 75.7 (d, ${}^{2}J(P-C) = 4.0 \text{ Hz}$), 125.3, 127.0, 128.1, 129.9 (d, ${}^{2}J(P-C) = 10.0 \text{ Hz}$), 131.6 (d, ${}^{2}J(P-C) = 7.0 \text{ Hz}$), 134.0, 134.8, 135.2, 135.4, 135.5, 135.6, 166.7, 167.5; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 17.6; LC/MS m/z 589 [M + 1]⁺. Anal. calcd for C₂₉H₃₃O₁₁P: C 59.18; H 5.65. Found: C 59.15; H 5.58. This compound was crystallized from ethyl acetate at 25 °C. Isomeric compounds 36(c,d): These compounds were separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield quantitative [36a+36b+36(c,d)] by ³¹P NMR, 0.44 g (isolated, 43%, $36(c,d) \sim 1:1$); gummy; IR (neat, cm⁻¹) 2963, 2928, 1734, 1447, 1416, 1261, 1094, 1019, 801; ¹H NMR (400 MHz, CDCl₃) δ 0.66 and 0.67 (2 s, 6H), 0.81 (t, ³J(H–H) = 7.0 Hz, 3H, isomer **36d**), 1.27 and 1.29 (2 s, 6H), 1.57 (d, ${}^{3}J(H-H) = 4.4$ Hz, 3H, isomer 36c), 3.54-3.77 (m, 4H), 3.82-3.83 (2 s, 6H), 3.86-3.94 (m, 4H), 3.96–3.97 (2 s, 6H), 4.06 (s, 2H, isomer **36c**), 5.38–5.46 (m, 2H), 5.75–5.81 (m, 1H), 6.67 (d, J(H-H) = 11.2 Hz, isomer **36d**), 7.52–8.70 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 20.5, 20.5_2 , 22.0, 22.1, 32.1_0 , 32.1_1 , 32.2, 35.7 (d, ${}^3J(P-C) = 5.0$ Hz), 52.7, 53.1, 76.9, 77.0, 125.2, 125.3, 125.4, 125.9, 126.1, 126.2, $126.6 (d, {}^{3}J(P-C) = 4.0 Hz), 126.9, 127.1 (d, {}^{3}J(P-C) = 4.0 Hz),$ 127.6, 127.9, 128.0, 128.5 (d, ${}^{2}J(P-C) = 12.0$ Hz), 128.9, 129.0, $131.5, 131.7, 133.6, 133.7, 133.9 (d, {}^{2}J(P-C)=12.0 Hz), 135.0 (d,$ ${}^{3}J(P-C) = 4.0 \text{ Hz}$, 138.5, 138.8 (d, ${}^{2}J(P-C) = 11.0 \text{ Hz}$), 142.2 (d, ${}^{2}J(P-C) = 12.0 \text{ Hz}$) 167.5, 168.1; ${}^{31}P \text{ NMR}$ (162 MHz, CDCl₃) δ 9.7 and 11.1; LC/MS m/z 447 [M + 1]⁺. Anal. calcd for C₂₃H₂₇O₇P: C 61.88; H 6.10. Found: C 61.75; H 6.22.

Compounds 37(a-d). These compounds were prepared by a procedure similar to that for 30a-c by using allenylphosphonate 10 (0.80 g, 2.63 mmol) and DMAD (1.34 g, 7.89 mmol). Compound 37a: It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield quantitative $[37a+37b+37(c,d), ratio 3:2:5 by {}^{31}P NMR], 0.25 g (isolated, 25\%, 37a); mp 128-130 °C; IR (KBr, cm⁻¹) 2973, 2926, 1728, 1472, 1370, 1285,$ 1059, 826, 700; ¹H NMR (400 MHz, CDCl₃) δ 0.89 and 1.07 (2 s, 6H), 1.26 and 1.36 (2 t, ${}^{3}J(H-H) = 6.0$ Hz each, 6H), 2.39 (s, 3H), 3.86-4.13 (m, 4H), 4.25 and 4.32 (2 qrt, 4H), 5.46 (d, ${}^{2}J(P-H) =$ 24.0 Hz, 1H), 7.22-8.02 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 14.0, 19.8, 21.0, 21.5, 32.4 (d, ${}^{3}J(P-C) = 6.0$ Hz), 43.0 $(d, {}^{1}J(P-C) = 134.0 \text{ Hz}), 61.4, 61.7, 75.9, and 76.1 (2 d, {}^{2}J(P-C) = 6.0 \text{ Hz}), 127.3, 128.6, 129.5 (d, {}^{2}J(P-C) = 8.0 \text{ Hz}), 132.0 (d, {}^{3}J(P-C) = 5.0 \text{ Hz}), 132.1 (d, {}^{2}J(P-C) = 11.0 \text{ Hz}), 132.7,$ 132.8, 135.6 (d, ${}^{3}J(P-C) = 6.0$ Hz), 135.7, 168.0₀, 168.0₂; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 19.1; LC/MS m/z 475 [M + 1]⁺. Anal. calcd for C₂₅H₃₁O₇P: C 63.28; H 6.59. Found: C 63.41; H 6.52. Compound 37b: It was separated by using ethyl acetate/ hexane (3:2) mixture as the eluent. Yield quantitative [37a+37b+37(c,d)] by ³¹P NMR, 0.25 g (isolated, 15%, **37b**); mp 124–126 °C; IR (KBr, cm⁻¹) 2975, 2926, 1728, 1727, 1470, 1414, 1370, 1198, 1061, 1013, 824, 700; ¹H NMR (400 MHz, CDCl₃) & 0.82 and 1.00 (2 s, 6H), 1.10 and 1.29 (2 t, 12H, ${}^{3}J(H-H) = 6.6$ and 6.8 Hz respectively), 1.81 (d, ${}^{3}J(H-H) = 6.0$ Hz, 3H), 3.67 (dd \rightarrow t, ^{2,3} $J \approx 12.0$ Hz each, 2H), 3.84 (dd \rightarrow t, ^{2,3} $J \approx$ 12.0 Hz each, 2H), 4.12 and 4.26 (2 qrt, 8H), 5.74-5.86 (m, 2H),

 $6.43 (d, {}^{2}J(P-H) = 15.6 Hz, 1H), 7.19-7.46 (m, 5H); {}^{13}C NMR$ $(100 \text{ MHz}, \text{CDCl}_3) \delta 13.5, 14.0, 18.7, 21.3, 21.7, 32.5 \text{ (d, }^{3}J(\text{P}-\text{C}) =$ 6.9 Hz), 44.9 (d, ${}^{1}J(P-C) = 138.5$ Hz), 61.8, 62.1, 75.9, 76.0, 125.6, 126.9, 128.0, 130.1 (d, ${}^{2}J(P-C) = 8.9$ Hz), 131.1 (d, $^{2}J(P-C) = 7.4$ Hz), 133.5, 134.8, 135.2 (d, $^{3}J(P-C) = 5.4$ Hz), $135.7 (d, {}^{3}J(P-C) = 6.4 Hz), 166.2, 167.1; {}^{31}P NMR (162 MHz), 162.167.1; {}^{31}P NMR (162 MHz), 162.1; {}^{31}P NMR (162 MHz), 162.167.1; {}^{31}P NMR (162 MHz), 162.1; {}^{31}P NM$ CDCl₃) δ 17.2; LC/MS m/z 645 [M + 1]⁺. Anal. calcd for C₃₃H₄₁O₁₁P: C 61.48; H 6.41. Found: C 61.32; H 6.45. Isomeric compounds 37(c,d): These compounds were separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield quantitative [37a+37b+37(c,d)] by ³¹P NMR, 0.41 g (isolated, 42%, $37(c,d) \approx 1.1$; gummy; IR (neat, cm⁻¹) 2978, 2942, 1730, 1470, 1372, 1258, 1059, 828, 785; ¹H NMR (400 MHz, CDCl₃) δ 0.71 and 0.73 (2 s, 6H), 0.87 (t, ³*J*(H–H) = 8.0 Hz, 3H, isomer **37d**), 1.29-1.47 (m, 18H), 1.62 and 1.64 (2 br s, 5H), 3.58-3.97 (m, 8H), 4.12 (s, 2H, isomer 37c), 4.29-4.50 (m, 8H), 5.45-5.85 (m, 3H), 6.71 (d, ${}^{3}J(H-H) = 12.0$ Hz, 1H, isomer **37d**), 7.59-8.74 (m, 8H); 13 C NMR (100 MHz, CDCl₃) δ 13.3, 13.8, 14.0, 14.0, 14.1, 17.9, 20.4, 20.5, 21.9₅, 22.0₃, 22.1, 32.0, and 32.1 (2 d, ${}^{3}J(P-C) = 5.0$ and 7.0 Hz respectively), 35.5 (d, ${}^{3}J(P-C) =$ 5.0 Hz, isomer 37c), 61.8, 61.9, 62.3, 63.3, 76.3, and 76.5 (2 d, ${}^{3}J(P-C) = 7.0$ and 5.0 Hz respectively), 76.9₀, 76.9₂, 125.4, 125.6, 126.0, 126.1, 126.5 (d, ${}^{3}J(P-C) = 4.0$ Hz), 127.0 (d, ${}^{3}J(P-C) = 4.0$ Hz), 127.3, 127.5, 127.7, 127.9, 128.1, 128.5, 128.6, 128.7, 128.8, 131.6 (d, ${}^{2}J(P-C) = 18.0$ Hz), 132.1 (d, $^{2}J(P-C) = 17.0$ Hz), 133.5, 133.6, 133.7, 133.8, 133.9, 135.1 (d, ${}^{3}J(P-C) = 4.0$ Hz), 138.4, 138.8 (d, ${}^{2}J(P-C) = 11.0$ Hz), 142.3 (d, ${}^{2}J(P-C) = 9.0$ Hz), 167.0, 167.5, 167.6; ${}^{31}P$ NMR (162 MHz, $CDCl_3$) δ 9.9 and 11.3; $LC/MS m/z 475 [M + 1]^+$. Anal. calcd for C₂₅H₃₁O₇P: C 63.28; H 6.59. Found: C 63.15; H 6.62.

Compounds 38(a-d). These compounds were prepared by a procedure similar to that for 30a-c using allenylphosphonate 11 (0.35 g, 1.1 mmol) and DMAD (0.45 g, 3.2 mmol). Compound 38a: It was separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield quantitative [38a+38b+38(c,d), ratio 3:2:5 by ³¹P NMR], 0.13 g (isolated, 24%, **38a**); mp 132–134 °C; IR (KBr, cm⁻¹) 2963, 1742, 1721, 1601, 1433, 1281, 1196, 1076, 1032, 835, 787, 696, 517; ¹H NMR (400 MHz, CDCl₃) & 0.77 and $0.82 (2 \text{ t}, {}^{3}J(\text{H}-\text{H}) = 6.0 \text{ and } 8.0 \text{ Hz} \text{ respectively, 6H}, 1.19 \text{ and}$ 1.49 (2 qrt, 4H), 2.38 (s, 3H), 3.80 and 3.85 (2 s, 6H), 3.87–4.16 (m, 4H), 5.45 (d, ${}^{2}J(P-H) = 24.0$ Hz, 1H), 7.23–7.99 (m, 7H); ³C NMR (100 MHz, CDCl₃) δ 7.0, 7.1, 19.9, 22.5, 22.8, 37.4 (d, ${}^{3}J(P-C) = 5.7 \text{ Hz}$, 43.1 (d, ${}^{1}J(P-C) = 133.4 \text{ Hz}$), 52.4, 52.6, 73.4, and 73.6 (2 d, ${}^{3}J(P-C) = 6.5$ and 6.3 Hz respectively), 127.5, 128.7, 129.6, 129.7, 131.9, 132.3 (d, ${}^{3}J(P-C) = 5.1$ Hz), 132.6, 133.1, 135.8 (d, ${}^{3}J(P-C) = 5.0$ Hz), 136.1, 168.5₁, 168.5₄; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 19.9; LC/MS m/z 475[M + 1]⁺. Anal. calcd for C₂₅H₃₁O₇P: C 63.28; H 6.59. Found: C 63.22; H 6.65. Compound 38b: It was separated by using ethyl acetate/ hexane (2:3) mixture as the eluent. Yield quantitative [38a+38b+38(c,d)] by ³¹P NMR, 0.10 g (isolated, 14%, 38b); mp 124–126 °C; IR (KBr, cm⁻¹) 2965, 1732, 1636, 1439, 1395, 1256, 1075, 941, 831, 733, 704; ¹H NMR (400 MHz, CDCl₃) δ 1255, 1675, 171, 051, 755, 764, 11 Hull (160 Hull, 2001) 0.69 and 0.79 (2 t, ${}^{3}J(H-H) = 8.0$ Hz each, 6H), 1.13 and 1.37 (2 qrt, 4H), 1.83 (d, ${}^{3}J(H-H) = 4.0$ Hz, 3H), 3.62 and 3.79 (2 s, 12H), 3.93 (dd→t, ${}^{2,3}J \sim 12.0$ Hz, 2H), 4.18 (dd→t, ${}^{2,3}J \sim 10.0$ Hz, 2H), 5.74–5.86 (m, 2H), 6.42 (d, ${}^{2}J(P-H) = 16.0$ Hz, 1H), 7.21–7.47 (m, 5H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 7.0, 19.0, 22.3, 23.3, 37.4 (d, ${}^{3}J(P-C) = 5.0$ Hz), 44.8 (d, ${}^{1}J(P-C) = 138.0$ Hz), 52.7, 52.9, 73.0, and 73.4 (2 d, ${}^{3}J(P-C) = 6.0$ Hz each), 125.3, 127.1, 128.2, 130.1, 130.2, 131.8 (d, ${}^{3}J(P-C) = 7.0$ Hz), 134.0, 134.8, 135.4 (d, ${}^{2}J(P-C) = 22.0$ Hz), 135.6 (d, ${}^{3}J(P-C) =$ 6.0 Hz), 166.7, 167.6; ³¹P NMR (162 MHz, CDCl₃) δ 18.3; LC/MS m/z 618 [M + 1]⁺. Anal. calcd for C₃₁H₃₇O₁₁P: C 60.39; H 6.05. Found: C 60.29; H 6.12. Isomeric compounds 38(c,d): These compounds were separated by using ethyl acetate/hexane (1:2) mixture as the eluent. Yield quantitative [38a+38b+38(c.d)] by ³¹P NMR, 0.22 g (isolated, 42%, **38(c,d)**, ratio \approx 1:1); gummy;

IR (neat, cm⁻¹) 2967, 2888, 1734, 1647, 1445, 1254, 1075, 833, 783; ¹H NMR (400 MHz, CDCl₃) δ 0.67–1.10 (m, 23H), 1.63 (d, ${}^{3}J(H-H) = 4.0$ Hz, 3H, isomer **38c**), 1.77–1.86 (m, 2H, isomer 38d), 3.57-3.61 (m, 4H), 3.87, 3.88, 4.02, and 4.03 (4 s, 12H), 4.05-4.13 (m, 6H), 5.44-5.86 (m, 3H), 6.72 (dd, ${}^{3}J$ (H-H) = 11.8 Hz, ${}^{4}J(P-H) \approx 1.8$ Hz, 1H, isomer **38d**), 7.57–8.75 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 6.8, 7.3, 13.4, 18.0, 22.0, 22.1₀, 22.1₄, 22.9, 35.6 (d, ${}^{3}J(P-C) = 4.7$ Hz), 37.1 and 37.2 (2 d, ${}^{3}J(P-C) = 5.7$ and 5.0 Hz respectively), 52.7, 53.1₀, 53.1₃, 73.8, 74.0, 74.4 (d, ${}^{3}J(P-C) = 6.3$ Hz), 125.4, 125.5 (d, ${}^{3}J(P-C) = 4.0$ Hz), 126.1, 126.2, 126.8 (d, ${}^{3}J(P-C) = 3.7$ Hz), 127.1, 127.2, 127.6, 128.0₀, 128.0₂, 128.1, 128.2, 128.5, 128.8, 129.0, 131.6 (d, $^{2}J(P-C) = 16.8 \text{ Hz}$, 132.1 (d, $^{2}J(P-C) = 16.8 \text{ Hz}$), 133.6, 133.7, 133.8, 133.9, 134.0, 134.1, 134.9, 138.4, 138.8 (d, ${}^{2}J(P-C) = 11.0$ Hz), 142.1 (d, ${}^{2}J(P-C) = 12.6$ Hz), 167.6, 168.0₀, 168.0₂, 168.1; 31 P NMR (162 MHz, CDCl₃) δ 11.0 and 12.5; LC/MS *m*/*z* 474 $[M]^+$. Anal. calcd for $C_{25}H_{31}O_7P$: C 63.28; H 6.59. Found: C 63.45; H 6.51.

Compounds 39(a-d). These compounds were prepared by a procedure similar to that for 30a-c by using allenylphosphonate 11 (0.40 g, 1.20 mmol) and DMAD (0.62 g, 3.60 mmol). Compound 39a: It was separated by using ethyl acetate/hexane (1:1) mixture as the eluent. Yield quantitative [39a+39b+39(c,d), ratio 3:2:5 by ³¹P NMR] 0.13 g (isolated, 22%, **39a**); gummy; IR (neat, cm⁻¹) 2980, 2938, 1728, 1468, 1075, 1024, 835, 698; ¹H NMR (400 MHz, CDCl₃) δ 0.76 and 0.82 (2 t, ³J(H-H)=7.6 Hz each, 6H), 1.14 (m, 8H), 1.49 (qrt, 2H), 2.39 (s, 3H), 3.91 and 4.19 (m, 4H), 4.24 and 4.32 (2 qrt, 4H), 5.47 (d, ${}^{2}J(P-H) = 23.6$ Hz, 1H), 7.22–8.00 (m, 7H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 7.0, 7.1, 13.9, 14.1, 19.9, 22.5, 22.8, 37.3 (d, ${}^{3}J(P-C) = 5.0$ Hz), 43.0 $(d, {}^{1}J(P-C) = 134.0 \text{ Hz}), 61.4, 61.7, 73.4, and 73.5 (2 d, {}^{3}J(P-C) = 8.0 \text{ and } 7.0 \text{ Hz} \text{ respectively}), 127.4, 128.6, 129.6 (d, {}^{2}J(P-C) = 12.0 \text{ Hz}), 127.4, 128.6, 129.6 \text{ Hz})$ 8.0 Hz), 132.1 (d, ${}^{3}J(P-C) = 5.0$ Hz), 132.3, 132.8, 135.8, 168.0, 168.1; ³¹P NMR (162 MHz, CDCl₃) δ 20.0; LC/MS m/z 502 [M]⁺. Anal. calcd for C₂₇H₃₅O₇P: C 64.53; H 7.02. Found: C 64.59; H 6.93. Compound 39b: It was separated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative [**39a**+**39b**+**39(c,d**)] by ³¹P NMR 0.11 g (isolated, 13%, **39b**); gummy; IR (neat, cm⁻¹) 2975, 2938, 1732, 1603, 1470, 1416, 1287, 1192, 1076, 1032, 938, 843, 787, 700, 623; ¹H NMR (400 MHz, CDCl₃) δ 0.67 and 0.79 (2 t, ³*J*(H–H) = 7.4 Hz and 7.6 respectively, 6H), 1.05-1.44 (m, 16H), 1.82 (d, ${}^{3}J(H-H) = 6.4$ Hz, 3H), 3.92-4.32 (m, 12H), 5.79-5.87 (m, 2H), 6.43 (d, $^{2}J(P-H) = 16.0$ Hz, 1H), 7.20–7.47 (m, 5H); ¹³C NMR (100 MHz, $CDCl_3$) δ 7.0₀, 7.0₃, 13.5, 14.0, 18.8, 22.3, 23.4, 37.3 (d, ³*J*(P-C)=5.7 Hz), 45.0 (d, ¹*J*(P-C)=137.7 Hz), 61.8, 62.1, 73.1, and 73.4 (2d, ${}^{3}J(P-C) = 6.4$ and 6.8 Hz), 125.5, 126.9, 128.0, $130.4 (d, {}^{2}J(P-C) = 9.9 Hz), 131.5 (d, {}^{3}J(P-C) = 6.3 Hz), 133.5,$ 134.7, 135.0, 135.2, 135.6 (d, ${}^{3}J(P-C) = 7.7$ Hz), 166.2, 167.1; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 17.8; LC/MS *m*/*z* 672 [M]⁺. Anal. calcd for C₃₅H₄₅O₁₁P: C 62.49; H 6.74. Found: C 62.31; H 6.82. Isomeric compounds 39(c,d): These compounds were separated by using ethyl acetate/hexane (2:3) mixture as the eluent. Yield quantitative [39a+39b+39(c,d)] by ³¹P NMR, 0.24 g (isolated, 40%, **39(c,d)** ratio ~1:1); gummy; IR (neat, cm⁻¹) 2976, 2936, 1732, 1719, 1555, 1464, 1372, 1262, 1154, 1075, 1034, 938; ¹H NMR (400 MHz, CDCl₃) δ 0.70-1.07 (m, 23H), 1.35-1.46 (m, 12H), 1.62 (d, ${}^{3}J(H-H) = 4.4$ Hz, 3H, isomer **39c**), 1.77–1.86 (m, 2H, isomer **39d**), 3.57 and 3.60 (m each, 4H), 4.04-4.12 (m, 6H), 4.32 and 4.49 (2 qrt, 8H), 5.45-5.85 (m, 3H), 6.72 (d, ${}^{3}J(H-H) = 11.2$ Hz, 1H, isomer **39d**), 7.57-8.74 (m, 8H); ¹ ЗС NMR (100 MHz, CDCl₃) δ 6.8, 7.3, 13.4, 13.9, 14.0, 14.1₀, 14.1₃, $18.0, 21.9, 22.1, 22.8, 35.5 (d, {}^{3}J(P-C) = 3.6 Hz), 37.0 and 37.1 (2)$ d, ${}^{3}J(P-C) = 4.9$ and 5.4 Hz respectively), 61.8, 61.9, 62.3₀, 62.3₄, 74.3, 74.4, 125.1, 125.5 (d, ${}^{3}J(P-C) = 4.0$ Hz), 125.7 (d, ${}^{2}J(P-C) =$ 9.4 Hz), 125.9, 126.0, 126.1, 126.6, 126.7 (d, ${}^{3}J(P-C) = 4.1$ Hz), 126.9, 127.1 (d, ${}^{3}J(P-C) = 4.5$ Hz), 127.5, 127.7, 127.9, 128.0₀, $128.0_4, 128.1, 128.3, 128.7, 128.8, 129.7, 129.8 (d, {}^{3}J(P-C) = 5.3 Hz),$

131.3, 131.5, 131.7, 132.1, (d, ${}^{3}J(P-C) = 5.6$ Hz), 133.5, 133.7, 133.8, 133.9, 135.1, 135.2, 138.4, 138.8, 142.0 (d, ${}^{2}J(P-C) = 11.8$ Hz), 146.2, 147.5, 167.5, 167.6; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 11.1 and 12.6; LC/MS *m*/*z* 503 [M + 1]⁺. Anal. calcd for C₂₇H₃₅O₇P: C 64.53; H 7.02. Found: C 64.42; H 7.11.

(C) Reaction of Allenylphosphonates with 1,3-Diphenylisobenzofuran. (i) Synthesis of Compounds 41-52. Compound 41a. A mixture of allenylphosphonate 1 (0.30 g, 1.60 mmol) and 1,3diphenylisobenzofuran (0.65 g, 2.39 mmol) in p-xylene (3 mL) was heated at 80 °C for 6-12 h. The solvent was removed under reduced pressure and the product **41a** was isolated by using silica gel column chromatography [ethyl acetate/hexane (3:2)]. Yield quantitative by 31 P NMR, 0.40 g (isolated, 55%); mp 144–146 °C; IR (KBr, cm⁻¹) 2965, 1499, 1460, 1350, 1260, 1059, 993; ¹H NMR (400 MHz, CDCl₃) δ 0.87 and 1.04 (2 s, 6H), 3.46 and 3.61 (2 dd, ${}^{3}J(P-H) \approx 16.4 \text{ Hz}, {}^{2}J(H-H) \approx 11.6 \text{ Hz}, 2\text{H}), 4.00 \text{ (dd}, {}^{3}J(P-H) \approx 11.2 \text{ Hz}, {}^{2}J(H-H) \approx 6.0 \text{ Hz}, 1\text{H}), 4.08 \text{ (d}, {}^{2}J(P-H) = 18.0 \text{ Hz}, 1\text{H}), 4.15 \text{ (dd}, {}^{3}J(P-H) \approx 11.2 \text{ Hz}, {}^{2}J(H-H) \approx 6.0 \text{ Hz}, 1\text{H}), 5.34$ and 5.41 (br, 2H), 7.25-7.34 (m, 3H), 7.43-7.54 (m, 7H), 7.81 (d, ${}^{3}J(H-H) = 8.2$ Hz, 2H), 7.97 (d, ${}^{3}J(H-H) = 8.0$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 21.6, 22.3, 32.8 (d, ³J(P-C)=6.7 Hz), 47.9 (d, ${}^{1}J(P-C) = 144.3 \text{ Hz}$), 74.3 (d, ${}^{2}J(P-C) = 6.3 \text{ Hz}$), 74.8 (d, $^{2}J(P-C) = 5.5$ Hz), 89.2 (d, J(P-C) = 3.1 Hz), 90.2 (d, J(P-C) = 3.1 Hz) 6.7 Hz), 109.1 (d, J(P-C) = 4.3 Hz), 119.7, 122.5, 126.7, 127.0, 127.6, 128.1, 128.2, 128.5 (d, *J*(P-C)=8.3 Hz), 128.8, 135.0, 135.9, 144.7, 145.4, 146.1 (d, J(P-C) = 3.1 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 20.8; LC/MS m/z 459 [M + 1]⁺. Anal. calcd for C₂₈H₂₇O₄P: C, 73.35; H, 5.94. Found: C, 73.41; H, 5.86.

Compound 42a. This compound was prepared by a procedure similar to that for **41a** by using allenylphosphonate **2** (0.32 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by 31 P NMR; 0.57 g (81%); mp 231–232 °C; IR (KBr, cm⁻¹) 3063, 1659, 1603, 1451, 1300, 1236, 1051, 997; ¹H NMR (400 MHz, CDCl₃) δ 0.81 and 1.03 $(2 \text{ s}, 6\text{H}), 1.43 \text{ (d}, {}^{3}J(\text{P}-\text{H}) = 16.0 \text{ Hz}, 3\text{H}), 3.24 \text{ and } 3.72 \text{ (2 dd},$ ${}^{3}J(P-H) \approx 17.8$ Hz, ${}^{2}J(H-H) \approx 11.2$ Hz, 2H), 3.91 and 4.26 $(2 \text{ dd}, {}^{3}J(P-H) \sim 10.6 \text{ Hz}, {}^{2}J(H-H) \approx 4.0 \text{ Hz}, 2H), 5.33 \text{ (br s,}$ 2H), 7.17-7.19 (m, 2H), 7.37-7.58 (m, 8H), 7.85 (d, ${}^{3}J$ (H-H)= 7.6 Hz, 2H), 8.28 (d, ${}^{3}J(H-H) = 7.6$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 21.6, 22.1, 22.4, 33.0 (d, ${}^{3}J(P-C) = 6.0$ Hz), 52.6 (d, ${}^{1}J(P-C) = 142.0$ Hz), 74.3 (d, ${}^{2}J(P-C) = 7.0$ Hz), 74.7 (d, $^{2}J(P-C) = 6.0 \text{ Hz}$, 89.8 (d, $^{3}J(P-C) = 6.0 \text{ Hz}$), 91.3 (d, $^{2}J(P-C) =$ 7.0 Hz), 108.5 (d, J(P-C) = 4.0 Hz), 119.7, 121.8, 126.3, 127.0, 127.3, 127.4, 127.8, 127.9, 128.1, 128.5, 135.6 (d, *J*(P-C)=6.0 Hz), 144.7, 145.8, 152.4; ³¹P NMR (162 MHz, CDCl₃) δ 26.2, LC/MS m/z 474 [M + 1]⁺. Anal. calcd for C₂₉H₂₉O₄P: C, 73.71; H, 6.19. Found: C, 73.61; H, 6.28.

Compounds 43a-b. These compounds were prepared by a procedure similar to that for 41a by using allenylphosphonate 3 (0.39 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). Compound 43a: It was eluted by using ethyl acetate/ hexane (3:2) mixture as the eluent. Yield [43a+43b] quantitative by ³¹P NMR; 0.44 g (isolated, 70%, **43a**); mp 240–242 °C; IR (KBr, cm⁻¹) 2963, 1651, 1601, 1497, 1456, 1345, 1258, 1073, 997; ¹H NMR (400 MHz, CDCl₃) δ 0.59 (t, ³J(H-H) = 7.2 Hz, 3H), 0.80 (s, 3H), 0.90-0.98 (m, 5H), 1.17-1.33 (m, 2H), 1.92-2.13 (m, 2H), 3.11 and 3.71 (2 dd, ${}^{3}J(P-H) \sim 17.8$ Hz, ${}^{2}J(H-H) \sim$ 11.4 Hz, 2H), 3.81 and 4.23 (2 dd, ${}^{3}J(P-H) \sim 11.0$ Hz, ${}^{2}J(H-H) \approx$ 4.4 Hz, 2H), 5.26 and 5.37 (2 d, ${}^{2}J(H-H) = 4.4$ Hz, 2H), 7.13–7.59 (m, 10H), 7.86 (d, ${}^{3}J(H-H) = 7.6$ Hz, 2H), 8.36 (d, ${}^{3}J(H-H) = 7.6$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 13.5, 21.7, 22.4, 23.0, 25.8, 25.9, 32.7, 32.9 (d, ${}^{3}J(P-C) = 5.9$ Hz), 56.5 (d, ${}^{1}J(P-C) = 138.3$ Hz), 74.5 (d, ${}^{2}J(P-C) = 6.6$ Hz), 74.8 (d, ${}^{2}J(P-C) = 6.3$ Hz), 89.3 (d, ${}^{3}J(P-C) = 5.3$ Hz), 91.6 (d, ${}^{2}J(P-C) = 6.3$ Hz), 89.3 (d, ${}^{3}J(P-C) = 5.3$ Hz), 91.6 (d, ${}^{2}J(P-C) = 5.3$ Hz), 91.6 (d, {}^{2}J(P-C) = 5.3 Hz), 91.6 (d, {}^{ 7.3 Hz), 108.9 (d, J(P-C) = 5.1 Hz), 119.5, 121.8, 126.4, 126.9, 127.1, 127.4, 127.6, 127.9, 128.0, 128.5, 135.8, 145.4, 146.9, 149.2 (d, J(P-C)=3.7 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 25.7; LC/MS

m/z 515 [M + 1]⁺. Anal. calcd for C₃₂H₃₅O₄P: C, 74.69; H, 6.86. Found: C, 74.62; H, 6.99. Compound 43b: It was isolated by using ethyl acetate/hexane (7:3) mixture as the eluent. Yield [43a+43b] quantitative by ³¹P NMR; 0.12 g (isolated, 19%, **43b**); gummy; IR (neat, cm⁻¹) 2961, 1649, 1458, 1343, 1256, 1074, 1003, 909; ¹H NMR (400 MHz, CDCl₃) δ 0.63-0.76 (m, 7H), 0.98 (s, 3H), 1.07-1.63 (m, 4H), 2.28-2.37 (m, 1H), 3.34 and 3.77 (dd \rightarrow t, ³*J*(P–H) \approx ²*J*(H–H) \approx 10.7 Hz, 2H), 3.89 and 3.99 (dd \rightarrow t, ³*J*(P–H) \approx ²*J*(H–H) \sim 10.0 Hz, 2H), 5.41 and 5.42 $(2 \text{ s}, 2\text{H}), 7.15 - 7.56 \text{ (m}, 10\text{H}), 7.88 \text{ (d}, {}^{3}J(\text{H}-\text{H}) = 7.6 \text{ Hz}, 2\text{H}),$ $7.94 (d, {}^{3}J(H-H) = 7.6 Hz, 2H); {}^{13}C NMR (100 MHz, CDCl_3) \delta$ $13.8, 21.9, 22.4, 23.5, 27.3, 27.4, 32.8 (d, {}^{3}J(P-C) = 8.0 Hz), 34.9,$ $57.4 (d, {}^{1}J(P-C) = 135.0 Hz), 75.3 (d, {}^{2}J(P-C) = 6.0 Hz), 75.9 (d,$ $^{2}J(P-C) = 7.0$ Hz), 89.8, 91.0, 112.0 (d, J(P-C) = 6.0 Hz), 119.7, 122.1, 126.6, 127.5, 127.9, 128.3, 128.5, 135.5, 136.5, 145.3, 146.9 $(d, J(P-C) = 12.0 \text{ Hz}), 149.5 (d, J(P-C) = 6.0 \text{ Hz}); {}^{31}P \text{ NMR}$ $(162 \text{ MHz}, \text{CDCl}_3) \delta 22.1; \text{LC/MS} m/z 515 [M + 1]^+$. Anal. calcd for C₃₂H₃₅O₄P: C, 74.69; H, 6.86. Found: C, 74.62; H, 6.95.

Compound 44a. This compound was prepared by a procedure similar to that for 41a by using allenylphosphonate 4 (0.42 g, 1.60 mmol) and 1.3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.51 g (84%); mp 221–223 °C; IR (KBr, cm⁻¹) 2975, 1651, 1601, 1499, 1451, 1256, 1074, 1005; ¹H NMR (400 MHz, CDCl₃) δ 0.85 and 0.94 (2 s, 6H), 3.21 and 3.64 (dd, ${}^{3}J(P-H) \approx 17.0 \text{ Hz}, {}^{2}J(H-H) \approx 11.2 \text{ Hz},$ 2H), 3.85 and 4.21 (dd, ${}^{3}J(P-H) \approx 10.8 \text{ Hz}, {}^{2}J(H-H) \approx 5.4 \text{ Hz},$ 2H), 3.85 and 4.21 (dd, ${}^{3}J(P-H) \approx 10.8 \text{ Hz}, {}^{2}J(H-H) \approx 7.0 \text{ Hz},$ 2H), 5.33 and 5.64 (d, ${}^{2}J(H-H) \approx 4.6$ Hz, 2H), 7.00–7.01 (m, 3H), 7.16-7.27 (m, 5H), 7.48-7.56 (m, 4H), 7.62-7.65 $(m, 2H), 7.78 (d, {}^{3}J(H-H) = 6.8 Hz, 1H), 7.96 - 8.01 (m, 4H); {}^{13}C$ NMR (100 MHz, CDCl₃) δ 22.0, 22.7, 33.1 (d, ³*J*(P-C) = 6.6 Hz), 64.3 (d, ¹*J*(P-C) = 145.0 Hz), 75.1 (d, ²*J*(P-C) = 6.1 Hz), 75.3 (d, ²*J*(P-C) = 6.1 Hz), 89.5, 93.4 (d, ²*J*(P-C) = 6.6 Hz), 111.6, 119.4, 122.6, 126.3, 126.8, 126.9, 127.1, 127.3, 127.5, 128.0, 128.4, 128.7, 129.7, 129.8, 130.4 (d, J(P-C) =7.6 Hz), 133.0, 135.6 (d, J(P-C) = 10.5 Hz), 137.0, 137.2, 140.0, 145.2, 145.8, 151.1; ³¹P NMR (162 MHz, CDCl₃) δ 22.1; LC/MS m/z 535 [M+1]⁺. Anal. calcd for C₃₄H₃₁O₄P: C, 76.39; H, 5.84. Found: C, 76.32; H, 5.87. It was crystallized from dichloromethane/hexane (4:1) mixture at 25 °C.

Compounds 45a-b. These compounds were prepared by a procedure similar to that for 41a by using allenylphosphonate 5 (0.44 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). Compounds 45a: It was isolated by using ethyl acetate/ hexane (3:2) mixture as the eluent. Yield [45a+45b] quantitative by ³¹P NMR, 0.39 g (isolated, 66%, **45a**); mp 212–214 °C; IR (KBr, cm⁻¹) 2959, 1653, 1603, 1512, 1458, 1300, 1236, 1078, 1051, 1001; ¹H NMR (400 MHz, CDCl₃) δ 0.83 and 0.93 (2 s, 6H), 2.16 (s, 3H), 3.16-3.23 and 3.62-3.67 (2 m, 2H), 3.83-3.87 and 4.19–4.22 (2 m, 2H), 5.33 and 5.63 (d, ${}^{2}J(H-H) \sim 4.6$ Hz, 2H), 6.81 (d, ${}^{3}J(H-H) = 8.4$ Hz, 2H), 7.17–7.27 (m, 5H), 7.41–7.77 (m, 7H), 7.95-8.03 (m, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 20.9, 21.9, 22.7, 33.0 (d, ${}^{3}J(P-C) = 6.6$ Hz), 63.9 (d, ${}^{1}J(P-C) = 144.9$ Hz), 74.9 (d, ${}^{2}J(P-C) = 6.5$ Hz), 75.2 (d, ${}^{2}J(P-C) = 6.3$ Hz), 89.5 (d, ${}^{3}J(P-C) = 5.1$ Hz), 93.4 (d, ${}^{2}J(P-C) = 7.3$ Hz), 111.6 (d, *J*(P–C) = 4.7 Hz), 119.3, 122.6, 126.3, 127.1, 127.2, 127.3, 127.4, 127.7, 128.0, 128.6, 130.3 (d, J(P-C) = 7.2 Hz), 133.8, 135.7 (d, J(P-C) = 8.5 Hz), 145.4, 145.8, 151.2 (d, J(P-C) = 4.3 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 22.4; LC/MS m/z 549 [M + 1]⁺. Anal. calcd for C₃₅H₃₃O₄P: C, 76.63; H, 6.06. Found: C, 76.81; H, 6.21. **Compound 45b:** It was isolated by using ethyl acetate/hexane (7:3) mixture as the eluent. Yield [45a+45b] quantitative by ³¹P NMR, 0.16 g (isolated, 27%, **45b**); mp 194–196 °C; IR (KBr, cm⁻¹) 2963, 1655, 1460, 1370, 1300, 1246, 1049, 990; ¹H NMR (400 MHz, CDCl₃) & 0.84 and 1.08 (2 s, 6H), 2.29 (s, 3H), 2.93-2.99 and $3.90-4.09 (2 \text{ m}, 4\text{H}), 5.40 \text{ and } 5.48 (2 \text{ d}, {}^{2}J(\text{H}-\text{H}) \sim 4.8 \text{ Hz}, 2\text{H}),$ $6.65 \text{ (d, }^{3}J(H-H) = 7.6 \text{ Hz}, 1\text{H}), 6.87-7.02 \text{ (m, 5H)}, 7.27-7.62$ (m, 10H), 8.09 (d, ${}^{3}J(H-H) = 6.8$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 21.0, 22.0, 22.7, 32.9 (d, ³*J*(P–C) = 8.4 Hz), 65.3 (d, ¹*J*(P–C)=137.9 Hz), 74.7 (d, ²*J*(P–C)=6.3 Hz), 75.9 (d, ²*J*(P–C)=7.7 Hz), 91.1 (d, ³*J*(P–C) = 1.3 Hz), 91.8 (d, ²*J*(P–C) = 2.1 Hz), 113.3 (d, *J* = 7.1 Hz), 120.0, 123.0, 126.3, 127.7, 127.9 (d, *J* = 7.4 Hz), 128.6, 128.9, 130.2 (d, *J*=7.5 Hz), 134.4 (d, *J*=10.1 Hz), 137.1 (d, *J*=10.3 Hz), 144.2, 146.4 (d, *J*=11.5 Hz), 152.2 (d, *J*=8.5 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 20.1; LC/MS *m*/*z* 549 [M + 1]⁺. Anal. calcd for C₃₅H₃₃O₄P: C, 76.63; H, 6.06. Found: C, 76.58; H, 6.15.

Compounds 46a-b. These compounds were prepared by a procedure similar to that for 41a by using allenylphosphonate 7 (0.47 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). Compounds 46a: It was separated by using ethyl acetate/ hexane (3:2) mixture as the eluent. Yield [46a+46b] quantitative by ³¹P NMR, 0.40 g (isolated, 69%, 46a); mp 199–201 °C; IR (KBr, cm⁻¹) 2963, 1607, 1512, 1462, 1372, 1296, 1248, 1086, 939; ¹H NMR (400 MHz, CDCl₃) δ 0.83 and 0.94 (2 s, 6H), 3.16-3.23 (m, 1H), 3.61-3.66 (m, 4H), 3.83-3.87 and 4.20-4.23 (2 m, 2H), 5.34 (s, 1H), 5.63 (d, ²*J*(H-H) = 4.0 Hz, 1H), 6.54 (d, ${}^{3}J(P-H) = 8.8$ Hz, 2H), 7.17–7.26 (m, 5H), 7.45-7.77 (m, 7H), 7.96 (d, J(H-H) = 7.2 Hz, 2H), 8.01 (d, J(H-H) = 7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.9, 22.7, 33.0 (d, ${}^{3}J(P-C) = 6.5$ Hz), 55.0, 63.5 (d, ${}^{1}J(P-C) = 145.0$ Hz), 74.9 (d, ${}^{2}J(P-C) = 6.4$ Hz), 75.2 (d, ${}^{2}J(P-C) = 6.3$ Hz), 89.5 (d, ${}^{3}J(P-C) = 5.3$ Hz), 93.5 (d, ${}^{2}J(P-C) = 7.5$ Hz), 111.6 (d, J(P-C) = 4.7 Hz), 112.3, 119.3, 122.5, 126.3, 127.1, 127.2 (d, J(P-C) = 3.9 Hz), 127.4, 128.0, 128.7, 128.9, 131.6 (d, J(P-C) = 7.3 Hz), 135.7 (d, J(P-C) = 6.0 Hz), 145.3, 145.7, 151.3 (d, J(P-C) = 4.4 Hz), 158.2; ³¹P NMR (162 MHz, CDCl₃) δ 22.4; LC/MS m/z 563 $[M - 1]^+$. Anal. calcd for C₃₅H₃₃O₅P: C, 74.45; H, 5.89. Found: C, 74.42; H, 5.85. It was crystallized from dichloromethane/hexane (4:1) mixture at 25 °C. Compound 46b: It was separated by using ethyl acetate/hexane (7:3) mixture as the eluent. Yield [46a+46b] quantitative by ³¹P NMR, 0.11 g (isolated, 19%, **46b**); mp 209–210 °C; IR (KBr, cm⁻¹) 2965, 1607, 1512, 1460, 1341, 1256, 1188, 1074, 1007, 912; ¹H NMR (400 MHz, CDCl₃) δ 0.84 and 1.08 (2 s, 6H), 2.94 (dd \rightarrow t, ${}^{3}J(P-H) \approx {}^{2}J(H-H) \approx 11.4$ Hz, 1H), 3.77 (s, 3H), 3.89–4.09 (m, 3H), 5.40 and 5.48 (2 br s, 2H), 6.61–6.67 (m, 3H), 6.89–7.61 (m, 13H), 8.08 (d, ${}^{3}J(H-H) = 6.8$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 22.0, 22.7, 32.9 (d, ³*J*(P–C) = 8.1 Hz), 55.1, 65.0 (d, ¹*J*(P–C) = 138.0 Hz), 74.8 (d, ²*J*(P–C) = 5.8 Hz), 76.0 (d, ${}^{2}J(P-C) = 7.4$ Hz), 91.1, 91.8, 112.4, 113.3 (d, J =6.5 Hz), 120.0, 123.0, 126.3, 126.4, 127.8, 128.0, 128.6, 128.9, 129.1, 129.5, 131.6 (d, J = 7.2 Hz), 134.4, 137.0, 144.1, 146.4 (d, J = 11.4 Hz), 152.4 (d, J = 8.3 Hz), 158.7; ³¹P NMR (162 MHz, CDCl₃) δ 20.1; LC/MS m/z 565 [M + 1]⁺. Anal. calcd for C₃₅H₃₃O₅P: C, 74.45; H, 5.89. Found: C, 74.39; H, 5.86. This compound was crystallized from dichloromethane/hexane (4:1) mixture at 25 °C.

Compounds 47a-b. These compounds were prepared by a procedure similar to that for 41a by using allene 22 (0.18 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). Compound 47a: It was separated by using ethyl acetate/hexane (1:4) mixture as the eluent. Yield 0.32 g (isolated, 31%); mp 90–92 °C; IR (KBr, cm⁻¹) 2975, 2926, 1736, 1661, 1449, 1300, 1179, 997; ¹H NMR (400 MHz, CDCl₃) δ 1.15 (t, ³*J*(H–H)=7.2 Hz, 3H), 4.04–4.08 (m, 2H), 4.32 (s, 1H), 5.22 and 5.25 (2 s, 2H), $7.16-7.25 \text{ (m, 4H)}, 7.43-7.55 \text{ (m, 6H)}, 7.73 \text{ (d, }^{3}J(H-H) = 6.8$ Hz, 2H), 7.84 (d, ${}^{3}J(H-H) = 7.2$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) & 14.1, 55.1, 60.9, 89.1, 90.4, 107.8, 119.1, 123.0, 126.6, $127.2,\ 127.4_0,\ 127.4_2,\ 128.3,\ 128.4,\ 128.5,\ 128.6,\ 134.9,\ 136.8,$ 145.1, 146.1, 149.1, 170.3; LC/MS m/z 383 [M + 1]⁺. Anal. calcd for C₂₆H₂₂O₃: C, 81.65; H, 5.80. Found: C, 81.62, H; 5.75. It was crystallized from dichloromethane/hexane (4:1) mixture at 25 °C. Compound 47b: It was separated by using ethyl acetate/hexane (1:2) as the eluent. Yield 0.60 g (isolated, 59%); gummy; IR (neat, cm⁻¹) 2978, 1746, 1719, 1499, 1449, 1310, 1254, 1148, 1001; ¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, ³*J*(H–H) = 7.2 Hz, 3H), 3.85–4.08 (m, 3H), 5.19 and 5.23 (2 m, 2H), 7.11–7.27 (m, 3H), 7.37–7.68 (m, 9H), 7.95–7.98 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 13.8, 56.3, 60.7, 89.2, 90.2, 108.5, 119.5, 119.9, 125.2, 127.2, 127.5, 127.6, 127.8, 128.3, 128.4, 128.6, 134.6, 136.2, 145.2, 148.1, 149.6, 170.7; LC/MS *m*/*z* 381 [M – 1]⁺. Anal. calcd for C₂₆H₂₂O₃: C, 81.65; H, 5.80. Found: C, 81.65; H, 5.82.

Compound 48b. This compound was prepared by a procedure similar to that for **41a** by using allene **23** (0.32 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (1:2) mixture as the eluent. Yield 0.55 g (isolated, 78%); gummy; IR (neat, cm⁻¹) 2982, 1740, 1499, 1449, 1346, 1304, 1182, 1065, 1024, 993; ¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, ³*J*(H-H)=7.2 Hz, 3H), 1.21 (t, ³*J*(H-H)=7.2 Hz, 3H), 1.83 (d, ²*J*(H-H)=16.8 Hz, 1H), 3.52 (d, ²*J*(H-H)=16.8 Hz, 1H), 3.65-3.69 and 3.82-3.86 (2 m, 2H), 4.07 (q, ³*J*(H-H)=7.2 Hz, 2H), 5.22 and 5.60 (2 s, 2H), 7.25-7.61 (m, 10H), 7.79 (d, ³*J*(H-H)=7.6 Hz, 2H), 8.03-8.05 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 13.6, 14.1, 41.6, 60.5, 60.7, 60.8, 90.6, 91.2, 110.8, 120.3, 121.5, 125.8, 126.7, 128.1, 128.2, 128.5, 128.6, 128.7, 134.9, 135.6, 144.6, 146.0, 152.8, 170.7, 170.8; LC/MS *m*/*z* 469 [M + 1]⁺. Anal. calcd for C₃₀H₂₈O₅: C, 76.90; H, 6.02. Found: C, 76.85; H, 6.10.

Compound 49. This compound was prepared by a procedure similar to that for **41a** by using allenylphosphonate **8** (0.35 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was purified by column chromatography using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.58 g (isolated, 86%); mp 182–184 °C; IR (KBr, cm⁻¹) 2969, 1636, 1458, 1368, 1248, 1061, 1005, 874; ¹H NMR (400 MHz, CDCl₃) δ 0.99 (br s, 6H), 1.35 and 1.43 (2 s, 6H), 3.57–3.73 (m, 2H), 4.03–4.12 (m, 2H), 5.62 (d, ²*J*(P–H) = 12.8 Hz, 1H), 7.21–7.59 (m, 10H), 7.76 (d, ³*J*(H–H) = 7.2 Hz, 2H), 7.88 (d, ³*J*(H–H) = 8.4 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.5, 21.6, 24.1, 24.3, 32.5 (d, ³*J*(P–C) = 5.7 Hz), 50.6 (d, ³*J*(P–C) = 3.5 Hz), 91.6 (d, ³*J*(P–C) = 3.2 Hz), 75.1 (d, ²*J*(P–C) = 190.8 Hz), 120.6, 121.6, 125.7, 127.1, 127.5 (d, *J*(P–C) = 1.3 Hz), 147.2, 176.2 (d, ²*J*(P–C) = 6.0 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 12.8; LC/MS *m*/*z* 486 [M]⁺. Anal. calcd for C₃₀H₃₁O₄P: C, 74.06; H, 6.42. Found: C, 74.25; H, 6.45.

Compound 50. This compound was prepared by a procedure similar to that for **41a** by using allenylphosphonate **9** (0.41 g, 0.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.51 g (isolated, 83%); mp 228–230 °C; IR (KBr, cm⁻¹): 2930, 1634, 1447, 1265, 1063, 1009; ¹H NMR (400 MHz, CDCl₃) δ 0.98 and 1.04 (2 s, 6H), 1.17-1.77 (m, 7H), 2.23-2.29 and 2.52-2.61 (m, 3H), 3.60-3.74 and 4.11-4.19 (2 m, 4H), 5.54 (d, ${}^{2}J(P-H) = 10.5$ Hz, 1H), 7.30-7.58 (m, 9H), 7.85-7.93 (m, 3H), 8.01-8.03 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 21.4, 21.7, 21.9, 22.7, 23.4, 32.3, 32.5 (d, ${}^{3}J(P-C) = 5.6$ Hz), 32.8, 54.5 (d, ${}^{3}J(P-C) = 2.7$ Hz), 74.8 (d, ${}^{2}J(P-C) = 6.1$ Hz), 74.9 (d, ${}^{2}J(P-C) = 5.9$ Hz), 90.5 (d, ${}^{3}J(P-C) = 23.9$ Hz), 92.6, 104.4 (d, ${}^{1}J(P-C) = 192.7$ Hz), 120.9, 122.4, 127.0, 127.5, 127.6, 127.9, 128.2, 128.6, 128.7, 135.0, 138.0, 143.0, 147.4, 179.1 (d, ${}^{2}J(P-C) = 6.1$ Hz); ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 13.3; LC/MS m/z 528 [M + 1]⁺. Anal. calcd for C₃₃H₃₅O₄P: C, 75.27; H, 6.70. Found: C, 75.12; H, 6.81.

Compound 51. This compound was prepared by a procedure similar to that for **41a** by using allenylphosphine oxide **19** (0.43 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.49 g (isolated, 80%); mp 200–202 °C; IR (KBr, cm⁻¹) 2969, 1624, 1435, 1348, 1302, 1204, 1115, 995; ¹H NMR (400 MHz, CDCl₃)

δ 1.38 (s, 6H), 5.99 (d, ²*J*(P–H) = 20.8 Hz, 1H), 7.25–7.57 (m, 20H), 7.74 (d, ³*J*(H–H)=7.6 Hz, 2H), 7.86 (d, *J*(H–H)=7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 24.7, 24.9, 50.7 (d, ³*J*(P–C)= 3.0 Hz), 91.9 (d, ³*J*(P–C)= 17.0 Hz), 92.3, 112.1 (d, ¹*J*(P–C)= 102.0 Hz), 120.4, 121.8, 125.7, 127.0, 127.3, 127.5, 128.2, 128.3, 6, 128.4 (d, *J*(P–C)=5.0 Hz), 128.5, 128.7, 128.8, 130.7, 130.7₅ (d, *J*(P–C)= 2.0 Hz), 130.8, 131.3 (d, *J*(P–C)= 2.0 Hz), 134.5, 134.8, 135.0, 135.5, 135.8, 136.5, 142.9, 147.5, 174.1; ³¹P NMR (162 MHz, CDCl₃) δ 19.7; LC/MS *m*/*z* 539 [M + 1]⁺. Anal. calcd for C₃₇H₃₁O₂P: C, 82.51; H, 5.80. Found: C, 82.39; H, 5.87.

Compound 52. This compound was prepared by a procedure similar to that for 41a by using allenylphosphine oxide 20 (0.49 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.48 g (isolated, 85%); mp 208–210 °C; IR (KBr, cm⁻¹) 2922, 1618, 1435, 1345, 1198, 1101, 993; ¹H NMR (400 MHz, CDCl₃) δ 1.11-1.73 $(m, 7H), 2.20-2.76 (m, 3H), 5.86 (d, {}^{2}J(P-H) = 20.0 Hz), 7.27-$ 7.56 (m, 19H), 7.82 (d, ${}^{3}J(H-H) = 8.0$ Hz, 2H), 7.93–7.95 (m, 1H), 8.01 (d, ${}^{3}J(H-H) = 7.6$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, $CDCl_3$) δ 22.0, 22.8, 23.5, 33.1, 33.5, 54.4 (d, ³J(P-C) = 2.0 Hz), $90.8 (d, {}^{3}J(P-C) = 16.6 Hz), 92.6, 110.8 (d, {}^{1}J(P-C) = 102.6 Hz),$ 120.6, 122.6, 126.9, 127.4, 127.6, 127.9, 128.4 (d, *J* = 3.2 Hz), $128.4_6, 128.4_9, 128.6, 128.7, 130.8 (d, J=3.0 Hz), 130.9 (d, J=3.6$ Hz), 131.2₆, 131.3₀, 131.3₃, 134.5, 134.8, 135.2, 135.6, 135.9, 138.3, 143.4, 147.7, 176.8; ³¹P NMR (162 MHz, CDCl₃) δ 20.6; LC/MS m/z 580 [M + 1]⁺. Anal. calcd for C₄₀H₃₅O₂P: C, 83.02, H; 6.10. Found: C, 83.21; H, 6.03.

(ii) Synthesis of Compounds 53-56. Compound 53. A mixture of allenylphosphonate 12 (0.30 g, 1.1 mmol) and 1,3diphenylisobenzofuran (0.41 g, 1.52 mmol) in p-xylene (3 mL) was heated at 140 °C for 6 h. The solvent was removed in vacuo using a rotary evaporator. It was isolated by using silica gel column chromatography [ethyl acetate/hexane (4:1)]. Yield quantitative by ³¹P NMR, 0.50 g (isolated, 83%, **53**); mp 268–270 °C; IR (KBr, cm⁻¹) 2936, 1730, 1605, 1447, 1262, 1061, 1013; ¹H NMR (400 MHz, CDCl₃) δ 0.77 and 1.24 (2 s, 6H), 1.51–2.11 (m, 7H), 2.83–2.87 and 3.15–3.18 (m, 2H), 3.37–3.54 (m, 2H), 3.82–3.91 (m, 2H), 5.24 (d, ${}^{2}J$ (H–H) = 2.4 Hz, 1H), 5.57 (br s, 1H), 7.11–7.52 (m, 10H), 7.80 (d, ${}^{3}J$ (H–H)= 8.0 Hz, 2H), 7.94 (d, ${}^{3}J(H-H) = 7.2$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 20.5, 22.2, 26.8, 29.7, 31.4, 32.2 (d, ³*J*(P–C) = 5.6 Hz), 40.0 (d, J(P-C) = 9.2 Hz), 61.5 (d, J(P-C) = 20.9 Hz), $75.2 (d, {}^{2}J(P-C) = 6.8 Hz), 75.5 (d, {}^{2}J(P-C) = 6.9 Hz), 88.3, 90.2$ (d, ${}^{3}J(P-C) = 10.6$ Hz), 119.2 (d, J(P-C) = 4.9 Hz), 120.7 $(d, {}^{1}J(P-C) = 166.6 Hz), 121.3, 122.0, 125.4, 126.9, 127.3,$ 127.4 (d, J(P-C) = 6.3 Hz), 128.0, 128.4, 128.6, 141.1, 142.9(d, J(P-C) = 10.5 Hz), 146.0, 147.2 (d, J(P-C) = 12.4 Hz), 161.6(d, J(P-C) = 8.2 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 13.4; LC/MS m/z 539 [M + 1]⁺. Anal. calcd for C₃₄H₃₅O₄P: C, 75.82; H, 6.55. Found: C, 75.91; H, 6.71.It was crystallized from dichloromethane/hexane (10:1) mixture at 25 °C.

Compound 54. This compound was prepared by a procedure similar to that for **53** by using allenylphosphonate (**13**) (0.33 g, 1.1 mmol) and 1,3-diphenylisobenzofuran (0.41 g, 1.52 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.46 g (isolated, 80%); mp 140–142 °C; IR (KBr, cm⁻¹) 2938, 1601, 1448, 1265, 1076, 1032; ¹H NMR (400 MHz, CDCl₃) δ 0.81 and 0.87 (2 t, ³*J*(H–H) ~ 7.5 Hz, 6H), 1.06–1.17 (m, 2H), 1.26–1.30 (m, 1H), 1.67–1.81 and 1.88–1.93 (m, 6H), 2.07–2.10 (m, 2H), 2.85–2.89 and 3.15–3.19 (m, 2H), 3.38–3.41 (m, 1H), 3.67–3.85 (m, 2H), 4.01–4.15 (m, 1H), 5.25 (d, ²*J*(H–H) = 2.8 Hz, 1H), 5.59 (d, ²*J*(H–H)=2.4 Hz, 1H), 7.14–7.23 (m, 3H), 7.33–7.54 (m, 7H), 7.81–7.83 (m, 2H), 7.95–7.97 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 6.9, 7.2, 21.4, 22.4, 26.9, 29.7, 31.4, 32.2, 37.1 (d, ³*J*(P–C)=4.6 Hz), 40.0 (d, *J*(P–C)=9.3 Hz), 61.4 (d, *J*(P–C) = 21.1 Hz), 72.7 (d, ²*J*(P–C) = 7.1 Hz), 73.1 (d,

 ${}^{2}J(P-C) = 6.6 \text{ Hz}$, 88.3, 90.2 (d, ${}^{3}J(P-C) = 10.8 \text{ Hz}$), 119.1 (d, J(P-C) = 6.1 Hz), 121.3, 122.0, 125.4, 126.9, 127.3, 127.4, 127.5, 128.0, 128.4, 128.6, 141.1, 142.9 (d, J(P-C) = 10.3 Hz), 145.9, 147.2 (d, J(P-C) = 12.2 Hz), 161.4 (d, J(P-C) = 8.6 Hz), [the doublet due to ${}^{1}J(P-C)$ was not clear]; ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 14.8; LC/MS m/z 567 [M + 1]⁺. Anal. calcd for C₃₆H₃₉O₄P: C, 76.30; H, 6.94. Found: C, 76.41; H, 6.88.

Compound 55. This compound was prepared by a procedure similar to that for 53 by using allenylphosphonate 14 (0.38 g, 1.1 mmol) and 1,3-diphenylisobenzofuran (0.41 g, 1.52 mmol) It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by 31 P NMR, 0.45 g (isolated, 82%); mp 108–110 °C; IR (KBr, cm⁻¹) 2924, 1599, 1460, 1269, 1067, 1001; ¹H NMR (400 MHz, CDCl₃) δ 0.92 and 1.01 (2 s, 6H), 1.27 (br, 1H), 1.63–1.69 (br, 1H), 1.98 (br, 3H), 2.13–2.16 (br, 2H), 2.93-2.98 and 3.21-3.24 (2 m, 2H), 3.49-3.55 and 3.87-3.95 (m, 4H), 6.65 (br, 1H), 7.11–7.26 (m, 7H), 7.33–7.42 (m, 5H), 7.48–7.56 (m, 4H), 7.85–8.03 (m, 3H); ¹³C NMR (100 MHz, $CDCl_3$) δ 21.3, 22.2, 27.1, 31.0, 31.1, 32.5 (d, ${}^{3}J(P-C) = 6.0$ Hz), 40.6 (d, J(P-C) = 8.0 Hz), 62.1 (d, J(P-C) = 21.0 Hz), 74.1 (d, ${}^{2}J(P-C) = 5.0$ Hz), 75.2 (d, ${}^{2}J(P-C) = 6.0$ Hz), 88.1, 92.3 (d, J(P-C) = 9.0 Hz, 120.2 (d, ¹J(P-C) = 174.0 Hz), 120.9, 122.7, 125.5, 126.9, 127.3, 127.5, 127.6, 127.7, 128.2, 128.4, 128.7, 130.4, 132.3, 136.3, 139.7 (d, J(P-C) = 10.0 Hz), 142.2, 142.4, 142.6, 146.3, 164.1 (d, J(P-C) = 8.0 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 10.3; LC/MS m/z 615 [M + 1]⁺. Anal. calcd for C40H39O4P: C, 78.16; H, 6.39. Found: C, 78.23; H, 6.31.

Compound 56. This compound was prepared by a procedure similar to that for 53 by using allenylphosphonate 15 (0.28 g, 1.11 mmol) and 1,3-diphenylisobenzofuran (0.41 g, 1.52 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.49 g (isolated, 80%); gummy; IR (neat, cm⁻¹) 2932, 1599, 1447, 1240, 1022, 961; ¹H NMR (400 MHz, CDCl₃) δ 1.28–1.31 (m, 6H), 1.34–1.38 (m, 1H), 1.59-1.66 (m, 2H), 1.71-1.75 (m, 2H), 2.41-2.49 (m, 1H), 2.68-2.74 (m, 1H), 3.58-3.63 (m, 1H), 3.77-4.04 (m, 4H), 5.29 (d, ${}^{2}J(H-H) \sim 3.4$ Hz, 1H), 5.43 (d, ${}^{2}J(H-H) \sim 3.4$ Hz, 1H), 7.22-7.43 (m, 10H), 7.68-7.71 (m, 4H); ¹³C NMR (100 MHz, $CDCl_3$) $\delta 16.3 (d, {}^{3}J(P-C) = 3.0 \text{ Hz}), 16.4 (d, {}^{3}J(P-C) = 2.9 \text{ Hz}),$ 22.0, 23.2, 27.5, 31.8 (d, J(P-C)=8.1 Hz), 56.4 (d, J(P-C)=21.2Hz), $61.3 (d, {}^{2}J(P-C) = 6.1 Hz)$, $61.5 (d, {}^{2}J(P-C) = 5.9 Hz)$, 89.6 $(d, {}^{3}J(P-C) = 7.5 \text{ Hz}), 89.8 (d, {}^{4}J(P-C) = 1.8 \text{ Hz}), 117.7 (d,$ J(P-C) = 5.3 Hz), 122.5, 123.1, 124.7 (d, ${}^{1}J(P-C) = 180.7$ Hz), $126.0, 127.1, 127.4 (d, J(P-C) = 7.4 Hz), 127.5, 127.7_9, 127.8_4,$ 128.3, 141.5, 143.6, 147.5, 150.1 (d, *J*(P-C)=10.2 Hz), 160.7 (d, J(P-C) = 9.7 Hz; ³¹P NMR (162 MHz, CDCl₃) δ 18.9; LC/MS m/z527 $[M + 1]^+$. Anal. calcd for C₃₃H₃₅O₄P: C, 75.27; H, 6.70. Found: C, 75.15; H, 6.81.

Compound 57. This compound was prepared by a procedure similar to that for **41a** by using allenylphosphonate **12** (0.30 g, 1.60 mmol) and 1,3-diphenylisobenzofuran (0.65 g, 2.39 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. In this reaction, compound 53 (20%, 31 P NMR) was also formed. Yield [53 + 57] quantitative by 31 P NMR, 0.41 g (isolated, 68%, **57**); mp 202–204 °C; IR (KBr, cm⁻¹) 2926, 1827, 1655, 1601, 1451, 1343, 1298, 1256, 1076, 1005, 912; ¹H NMR (400 MHz, CDCl₃) δ 0.81 (s, 3H), 0.95 (br s, 4H), 1.15-1.26 (m, 3H), 1.71-2.05 (m, 4H), 3.06-3.13 (m, 1H), 3.65-3.77 (m, 2H), 4.18–4.22 (m, 1H), 5.25 and 5.46 (2 d, ${}^{2}J(H-H) \sim 4.0$ Hz, 2H), 6.03 (br s, 1H), 7.15–7.67 (m, 10H), 7.87 (d, ${}^{3}J(H-H) = 8.0$ Hz, 2H), 8.25 (d, ${}^{3}J(H-H) = 7.6$ Hz, 2H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 21.6, 21.9, 22.7, 22.9, 26.0, 28.3 (d, *J*(P-C) = 5.9 Hz), $33.0 (d, {}^{3}J(P-C) = 6.4 Hz), 65.1 (d, {}^{1}J(P-C) = 142.5 Hz), 74.7 (d, {}^{3}J(P-C) = 142.5 Hz), 74.7 (d, {}^{3}J$ $^{2}J(P-C) = 6.5$ Hz), 75.0 (d, $^{2}J(P-C) = 6.5$ Hz), 89.2 (d, $^{3}J(P-C) =$ 5.1 Hz), 93.1 (d, ${}^{2}J(P-C) = 7.3$ Hz), 110.8 (d, J(P-C) = 5.1 Hz), 119.3, 122.3, 126.3, 127.1 (d, J(P-C) = 13.8 Hz), 127.3₇, 127.4₂, 127.7, 127.9, 128.5, 130.6 (d, J(P-C) = 8.9 Hz), 132.8, 135.8, 136.0, 145.7, 146.0, 149.6 (d, J(P-C) = 4.3 Hz); ³¹P NMR

(162 MHz, CDCl₃) δ 23.4; LC-MS m/z 537 [M – 1]⁺. Anal. calcd for C₃₄H₃₅O₄P: C, 75.82; H, 6.55. Found: C, 75.65; H, 6.71.

(D) Reaction of Allenylphosphonates with Anthracene. Synthesis of [4 + 2] Cycloaddition Compounds 58–68 and the [2 + 2]Dimerized Product 70. Compounds 58 and 64. A mixture of allenylphosphonate 1 (0.30 g, 1.60 mmol) and anthracene (1.00 g, 5.58 mmol) in p-xylene (3 mL) was heated under reflux for 24 h. The solvent was removed under reduced pressure. Excess anthracene was removed by using a short column (neutral alumina, ethyl acetate/hexane: 1:4) and the crude products 58 and 64 (same R_f values) were eluted by using ethyl acetate/hexane (3:2) mixture. Pure compounds 58 (powdery) and 64 (crystals) were separated by hand-picking after crystallization from dichloromethane/hexane (4:1). Compound 58: Yield [58 + 64] quantitative by ³¹P NMR, 0.41 g (isolated, 10%, **58**); mp 176–178 °C; IR (KBr, cm⁻¹) 3010, 2885, 2298, 1467, 1270, 1056, 1003, 911; ¹H NMR (400 MHz, CDCl₃) δ 0.89 and 1.03 (2 s, 6H), 3.15 (d, ²*J*(P–H) = 23.2 Hz, 1H), 3.42–3.45 and 3.72–3.76 (2 m, 2H), 3.94 and 4.15 (2 dd, ³*J*(P–H) = 10.8 Hz, ${}^{2}J(H-H) \approx 6.4$ Hz, 2H), 4.80-4.82 (m, 2H), 5.18 and 5.36 (2 d, ${}^{2}J(H-H) = 4.8$ Hz, 2H), 7.11–7.42 (m, 8H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 21.7, 22.3, 32.8 (d, ³J(P-C) = 6.2 Hz), 43.0 (d, ${}^{1}J(P-C) = 138.3 \text{ Hz}$, 45.2, 55.4 (d, ${}^{3}J(P-C) = 4.0 \text{ Hz}$), 74.5 and 75.3 (2 d, ${}^{2}J(P-C) = 6.3$ Hz), 111.3 (d, ${}^{2}J(P-C) = 6.7$ Hz), 123.4, 123.5, 123.6, 123.7, 125.4, 126.2, 126.3, 126.6, 140.1, 141.3, 142.0, 142.1, 143.0; ³¹P NMR (162 MHz, CDCl₃) δ 22.8; LC/ MS *m*/*z* 367 [M+1]⁺; Anal. Calcd. for C₂₂H₂₃O₃P: C, 72.12; H, 6.33. Found: C, 72.35; H, 6.26. Compound 64: Yield [58 + 64] quantitative by ³¹P NMR, 0.06 g (isolated, 10%, 24); mp 168-172 °C; IR (KBr, cm⁻¹) 2922, 2852, 2301, 1627, 1463, 1264, 1060, 1007, 909; ¹H NMR (400 MHz, CDCl₃) δ 0.99 and 1.05 (2 s, 6H), 2.83-2.85 (m, 2H), 3.67-4.12 (m, 4H), 4.49 (br s, 1H), 4.84 (s, 1H), 5.78 (d, ${}^{2}J(P-H) = 19.6$ Hz, 1H) 7.11–7.32 (m, 8H); ¹³C NMR (100 MHz, CDCl₃) δ 21.7, 22.3, 32.8 (d, ³*J*(P–C) \approx 6.2 Hz), 36.0, 44.6, 58.1 (d, ${}^{3}J(P-C) = 23.3$ Hz), 74.9, 75.0, 106.4 (d, ${}^{1}J(P-C) = 187.3 \text{ Hz}$), 123.7, 124.0, 126.3, 126.7, 139.8, 143.0; ${}^{31}P \text{ NMR} (162 \text{ MHz}, \text{CDCl}_3) \delta 13.6; \text{ LC/MS } m/z 367 [M + 1]^+.$ Anal. calcd for C₂₂H₂₃O₃P: C, 72.12; H, 6.33. Found: C, 72.05; H, 6.38. It was crystallized from dichloromethane/hexane (4:1) mixture at 25 °C.

Compound 59. This compound was prepared by a procedure similar to that for 58 and 64 by using compound 2 (0.32 g, 1.60mmol) and anthracene (0.99 g, 5.58 mmol). It was formed along with self-dimerized product 70 (yield: 15%) The eluent used for compound **59** was ethyl acetate/hexane (3:2) mixture. Yield [59 + 70] quantitative by ³¹P NMR, 0.38 g (isolated, 67%, **59**); mp 208–210 °C; IR (KBr, cm⁻¹) 2967, 1470, 1372, 1277, 1059, 1003, 831; ¹H NMR (400 MHz, CDCl₃) δ 0.83 and 1.00 (2 s, 6H), $1.25 (d, {}^{3}J(P-H) = 16.0 Hz, 3H), 3.24-3.31 (m, 1H), 3.68-3.84$ (m, 2H), 4.18-4.22 (m, 1H), 4.55 (br, 1H), 4.75 (s, 1H), 5.09 and $5.37 (2 \text{ d}, 2\text{H}, {}^{2}J(\text{H}-\text{H}) \approx 4.8 \text{ Hz}), 7.10-7.44 (m, 8\text{H}); {}^{13}\text{C} \text{NMR}$ $(100 \text{ MHz}, \text{CDCl}_3) \delta 21.7, 22.2, 24.8 \text{ (d, }^2J(P-C) = 1.8 \text{ Hz}), 32.8$ $(d, {}^{3}J(P-C) = 6.3 \text{ Hz}), 46.0 (d, {}^{1}J(P-C) = 139.4 \text{ Hz}), 51.8, 55.8$ (d, ${}^{3}J(P-C) = 3.0$ Hz), 74.6 and 75.4 (2 d, ${}^{2}J(P-C) \approx 6.8$ Hz), 111.0 (d, ${}^{2}J(P-C) = 6.8$ Hz), 123.0, 123.2, 125.6, 125.9, 126.1, 126.3, 126.6, 140.0, 140.1, 141.0, 141.1 (d, J(P-C) = 3.1 Hz), $142.6 (d, J(P-C) = 2.9 Hz), 148.6; {}^{31}P NMR (162 MHz, CDCl_3)$ δ 26.9; LC/MS m/z 381 [M + 1]⁺. Anal. calcd for C₂₃H₂₅O₃P: C, 72.62; H, 6.62. Found: C, 72.65; H, 6.56.

Compound 60. This compound was prepared by a procedure similar to that for **58** and **64** by using allenylphosphonate **3** (0.39 g, 1.60 mmol) and anthracene (0.99 g, 5.58 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.35 g (isolated, 68%); mp 82–84 °C; IR (KBr, cm⁻¹) 3042, 2957, 1640, 1464, 1370, 1227, 1053; ¹H NMR (400 MHz, CDCl₃) δ 0.81–0.96 (m, 11H), 1.08–1.22 (m, 2H), 1.18–1.93 (m, 2H), 3.27 and 3.60 (2 dd, ³*J*(P–H) \approx 15.5 Hz, ²*J*(H–H) \approx 11.0 Hz, 2H), 3.81 and 4.15

(2 dd, ${}^{3}J(P-H) \approx 10.8$ Hz, ${}^{2}J(H-H) \approx 6.0$ Hz, 2H), 4.74 (s, 1H), 4.84 and 5.06 (2 d, ${}^{2}J(H-H) \approx 4.0$ Hz, 1H), 5.33 (d, ${}^{3}J(P-H) = 5.2$ Hz, 1H), 7.07–7.12 (m, 4H), 7.24–7.46 (m, 4H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 13.8, 22.0, 22.5, 23.2, 26.8, 32.8 (d, ${}^{3}J(P-C) = 6.6$ Hz), 39.1, 48.2, 50.1 (d, ${}^{1}J(P-C) = 136.9$ Hz), 56.0 (d, ${}^{3}J(P-C) =$ 3.2 Hz), 74.5 and 75.2 (2 d, ${}^{2}J(P-C) \approx 6.5$ Hz), 110.3 (d, J(P-C) =6.7 Hz), 123.0 (d, J(P-C) = 6.8 Hz), 125.2, 125.8 (d, ${}^{3}J(P-C) = 3.5$ Hz), 126.0, 126.2, 126.5, 139.8, 140.0, 140.6 (d, J(P-C) = 2.8 Hz), 142.3, 142.4, 149.6 (d, J(P-C) = 5.3 Hz); ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 26.1; LC/MS m/z 424 [M + 1]⁺. Anal. calcd for C₂₆H₃₁O₃P: C, 73.91; H, 7.40. Found: C, 74.12; H, 7.48.

Compound 61. This compound was prepared by a procedure similar to that for 58 and 64 by using allenylphosphonate 4(0.42 g,1.60 mmol) and anthracene (0.99 g, 5.58 mmol). It was isolated by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.35 g (isolated, 70%); mp 176-178 °C; IR (KBr, cm⁻¹) 3065, 2965, 1638, 1495, 1399, 1370, 1233, 1049; ¹H NMR (400 MHz, CDCl₃) δ 0.83 and 0.87 (2 s, 6H), 3.25-3.31 and 3.57-3.64 (2 m, 2H), 3.82-3.86 and 4.13-4.16 (2 m, 2H), 4.91 (s, 1H), 4.98 (d, ${}^{3}J(P-C) = 4.0$ Hz, 1H), 5.25 and 5.78 (2 d, ${}^{2}J(H-H) \sim 4.2$ Hz, 2H), 6.61 (d, ${}^{3}J(H-H) =$ 7.2 Hz, 1H), 6.77 (\sim t, ${}^{3}J$ (H–H) \sim 7.4 Hz, 1H), 6.98 (\sim t, ${}^{3}J(H-H) = 7.2$ Hz, 1H), 7.10–7.55 (m, 10H); ${}^{13}C$ NMR (100 MHz, CDCl₃) δ 22.1, 22.5, 33.0 (d, ${}^{3}J(P-C) = 6.3$ Hz), 55.6, 56.7, 56.9 (d, ${}^{1}J(P-C) = 139.4$ Hz), 75.1 and 75.8 (2 d, ${}^{2}J(P-C) \sim 6.3$ Hz), 114.9 (d, ${}^{2}J(P-C) = 6.0$ Hz), 122.9, 123.3, 125.5, 125.8, 126.1, 126.2, 126.3, 126.6, 126.9, 127.8, 128.2 (d, J(P-C) = 4.7 Hz), 139.1, 139.8, 140.1, 140.2, 141.3, 142.5, 144.7; ³¹P NMR (162 MHz, CDCl₃) δ 23.5; LC/MS m/z 443 [M + 1]⁺. Anal. calcd for C₂₈H₂₇O₃P: C, 76.00; H, 6.15. Found: C, 76.15; H, 6.14.

Compound 62. This compound was prepared by a procedure similar to that for 58 and 64 by using allenylphosphonate 5 (0.44 g, 1.60 mmol) and anthracene (0.99 g, 5.58 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.33 g (isolated, 67%); mp 144-146 °C; IR (KBr, cm⁻¹) 2967, 1640, 1512, 1460, 1368, 1233, 1051, 1009; ¹H NMR (400 MHz, CDCl₃) δ 0.82 and 0.88 (2 s, 6H), 2.22 (s, 3H), 3.23-3.30 and 3.57-3.63 (2 m, 2H), 3.82-3.85 and 4.13-4.16 (2 m, 2H), 4.89 (s, 1H), 4.96 (s, 1H), 5.23 (s, 1H), 5.75 (s, 1H), 6.64–7.00 (m, 6H), 7.13–7.55 (m, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 20.9, 22.1, 22.5, 32.9 (d, ³*J*(P-C) = 3.8 Hz), 55.6, 56.7 (d, ${}^{1}J(P-C) = 138.8$ Hz), 56.8, 75.0, 75.7, 114.7, 122.9, 123.2, 125.6, 125.8, 126.1, 126.3, 126.5, 128.1, 128.6, 136.0, 136.4, 140.0, 140.2 140.3, 141.4, 142.6, 145.0; ³¹P NMR (162 MHz, CDCl₃) δ 23.8; LC/MS m/z 457 [M + 1]⁺. Anal. Calcd for C₂₉H₂₉O₃P: C, 76.30; H, 6.40. Found: C, 76.55; H. 6.48.

Compound 63. This compound was prepared by a procedure similar to that for 58 and 64 by using allenylphosphonate 7 (0.47 g, 1.60 mmol) and anthracene (0 99 g, 5.58 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ${}^{31}P$ NMR, 0.33 g (69%); mp 152–154 °C; IR (KBr, cm⁻¹) 2957, 1607, 1510, 1464, 1252, 1051, 1009; ¹H NMR (400 MHz, CDCl₃) δ 0.82 and 0.88 (2 s, 6H), 3.27 (dd, ${}^{3}J(P-H) \approx 16.0$ Hz, ${}^{2}J(H-H) \approx 10.9$ Hz, 1H), 3.61 (dd, ${}^{3}J(P-H) \approx 16.0 \text{ Hz}, {}^{2}J(H-H) \approx 10.9 \text{ Hz}, 1H$), 3.71(s, 3H), 3.83 (dd, ${}^{3}J(P-H) \approx 10.7 \text{ Hz}$, ${}^{2}J(H-H) \approx 5.7 \text{ Hz}$, 1H), 4.14 $(dd, {}^{3}J(P-H) \approx 10.7 \text{ Hz}, {}^{2}J(H-H) \approx 5.7 \text{ Hz}, 1H), 4.90 \text{ (s, 1H)},$ 4.95 (d, ${}^{3}J(P-H) = 4.4$ Hz, 1H), 5.24 and 5.76 (2 d, ${}^{2}J(H-H) \approx$ 4.8 Hz, 2H), 6.63–6.66 (m, 3H), 6.80 (\sim t, ³*J*(H–H) \approx 7.4 Hz, 1H), 6.99 (\sim t, ³*J*(H–H) = 7.2 Hz, 1H), 7.11–7.55 (m, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 22.0, 22.4, 32.9 (d, ³J(P-C) = 6.7 Hz), 55.0, 55.5, 56.1 (d, ${}^{1}J(P-C) = 139.3$ Hz), 56.6, 75.0, and 75.7 $(2 \text{ d}, {}^{2}J(P-C) \approx 6.7 \text{ Hz}), 113.0, 114.6 \text{ (d}, J(P-C) = 7.3 \text{ Hz}),$ 122.8, 123.1, 125.6, 125.9, 126.0, 126.1, 126.2, 126.5, 129.3 (d, J(P-C) = 5.3 Hz, 131.0 (d, J(P-C) = 3.4 Hz), 139.8 (d, J(P-C) =2.2 Hz), 140.1, 140.3, 141.2 (d, J(P-C) = 3.2 Hz), 142.4, 145.0

(d, J(P-C) = 5.4 Hz), 158.1; ³¹P NMR (162 MHz, CDCl₃) δ 24.0; LC/MS m/z 473 [M + 1]⁺. Anal. calcd for C₂₉H₂₉O₄P: C, 73.71; H, 6.19. Found: C, 73.85; H, 6.26.

Compounds 65 and 66. These compounds were prepared by a procedure similar to that for 58 and 64 by using allenylphosphine oxide 16 (0.38 g, 1.60 mmol) and anthracene (0.99 g, 5.58 mmol). The crude containing products 65-66 were isolated by using ethyl acetate/hexane (3:2) mixture. Pure compounds 65 and 66 were separated by hand-picking after crystallization from dichloromethane-hexane (4:1). Compound 66 appeared as block type of crystals while compound 65 was powdery. Compound 65: Yield [65 + 66] quantitative by ³¹P NMR; 0.12 g (isolated, 23%, 65); mp 180–182 °C; IR (KBr, cm⁻¹) 2930, 1624, 1468, 1435, 1177; ¹H NMR (400 MHz, CDCl₃) δ 3.72 (dd, $^{2}J(P-H) = 16.8 \text{ Hz}, {}^{3}J(H-H) \approx 2.4 \text{ Hz}, 1\text{H}), 4.21-4.23 \text{ (m, 1H)},$ 4.73 (s, 1H), 4.98-5.00 and 5.13-5.15 (2 m, 2H), 6.73 (~t, ${}^{3}J(H-H) \approx 7.2$ Hz, 1H), 6.87 (~t, ${}^{3}J(H-H) \approx 7.4$ Hz, 1H), 7.00 $(d, {}^{3}J(H-H) = 8.0 \text{ Hz}, 1\text{H}), 7.09-7.19 \text{ (m, 5H)}, 7.26-7.61 \text{ (m, })$ 10H); ¹³C NMR (100 MHz, CDCl₃) δ 44.7, 46.2 (d, ¹J(P-C) = 67.9 Hz), 56.4, 111.2 (d, ${}^{2}J(P-C) = 3.6$ Hz), 123.2, 123.3, 123.5, 125.6, 126.0, 126.2, 126.3, 126.5, 127.7, 127.8, 128.5, 128.7, 131.2, 131.4, 131.5, 131.8, 132.0, 132.1, 139.6, 140.5, 142.6, 143.3, $({}^{1}J(PC)$ due to PPh₂ group was difficult to assign); ${}^{31}P$ NMR (162 MHz, CDCl₃) δ 31.0; LC/MS m/z 419 [M + 1]⁺. Anal. calcd for C₂₉H₂₃OP: C, 83.24; H, 5.54. Found: C, 83.10; H, 5.48. Compound 66: Yield [65 + 66] quantitative by ³¹P NMR, 0.34 g (isolated, 65%, 66); mp 190-192 °C; IR (KBr, cm⁻¹) 2957, 2201, 1607, 1462, 1437, 1273, 1202, 1051, 999; ¹H NMR (400 MHz, CDCl₃) δ 2.29 (d, 3H, ⁴*J*(P–H) = 2.8 Hz), 4.80 (d, ³*J*(P–H) = 8.8 Hz, 1H), 4.97 (d, ⁴*J*(P–H) = 3.2 Hz, 1H), 6.89–7.00 (m, 6H), 7.30–7.46 (m, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 19.6 (d, ³*J*(P–C) = 4.8 Hz), 53.6 (d, ²*J*(P–C) = 12.2 Hz), $60.5 \text{ (d, } {}^{3}J(P-C) = 10.7 \text{ Hz}$), 123.0, 123.3, 124.9, 125.1, 128.6, 128.7, 131.0, 131.8, 131.9, 132.3, 132.7, 132.9 (d, ¹*J*(P-C) = 105.1 Hz), 133.7, 144.2 (d, J(P-C) = 2.7 Hz), 144.4 (d, J(P-C) =2.7 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 29.6; LC/MS m/z 419 [M + 1]⁺. Anal. calcd for C₂₉H₂₃OP: C, 83.24; H, 5.54. Found: C, 83.30; H, 5.59.

Compound 67. These compounds were prepared by a procedure similar to that for 58 and 64 by using allenylphosphine oxide 17 (0.41 g, 1.60 mmol) and anthracene (0.99 g, 5.58 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by 31 P NMR, 0.33 g (65%); mp 210–212 °C; IR (KBr, cm⁻¹) 3056, 2924, 1638, 1437, 1310, 1184, 1119, 1028; ¹H NMR (400 MHz, CDCl₃) δ 1.14 (d, ${}^{3}J(P-H) = 14.0$ Hz, 3H), 4.77–4.80 (m, 2H), 4.89 and 5.41 (d, $^{2}J(H-H) \approx 4.0$ Hz, 2H), 6.55 (~t, $^{3}J(H-H) \approx 7.2$ Hz, 1H), 6.64 $(\sim t, {}^{3}J(H-H) \approx 7.0 \text{ Hz}, 2H), 0.35 (\sim t, {}^{3}J(H-H) \approx 7.2 \text{ Hz}, HI), 0.04 (\sim t, {}^{3}J(H-H) \approx 7.0 \text{ Hz}, 1H), 7.01 (d, {}^{3}J(H-H) = 7.2 \text{ Hz}, 1H), 7.07-7.12 (m, 5H), 7.18-7.39 (m, 6H), 7.65 (\sim t, {}^{3}J(H-H) \approx 8.8 \text{ Hz}, 2H), 7.74 (\sim t, {}^{3}J(H-H) \approx 8.8 \text{ Hz}, 2H); {}^{13}C \text{ NMR} (100)$ MHz, CDCl₃) δ 26.8, 48.1 (d, ¹J(P-C) = 69.3 Hz), 51.5, 56.7, 112.0 (d, ${}^{2}J(P-C) = 5.4$ Hz), 122.8, 123.7, 125.8, 125.9, 126.1, 126.4, 126.6, 126.8, 127.5 (d, J(P-C) = 11.3 Hz), 127.9 (d, J(P-C) = 11.0 Hz), 130.3, 131.2, 131.6, 131.8 (d, J(P-C) = 7.5Hz), 132.8 (d, J(P-C) = 8.2 Hz), 140.5, 141.3 (d, J(P-C) = 10.2Hz), 143.3, 150.2; ³¹P NMR (162 MHz, CDCl₃) δ 31.5; LC/MS m/z 432 [M]⁺. Anal. calcd for C₃₀H₂₅OP: C, 83.31; H, 5.83. Found: C. 83.45: H. 5.72.

Compound 68. These compounds were prepared by a procedure similar to that for **58** and **64** by using allenylphosphine oxide **18** (0.51 g, 1.60 mmol) and anthracene (0.99 g, 5.58 mmol). It was purified by using ethyl acetate/hexane (3:2) mixture as the eluent. Yield quantitative by ³¹P NMR, 0.30 g (64%); mp 212–214 °C; IR (KBr, cm⁻¹) 3052, 2944, 1634, 1433, 1263, 1181, 1092, 945; ¹H NMR (400 MHz, CDCl₃) δ 4.83 (s, 1H), 4.86 (s, 1H), 5.60 and 5.83 (2 s, 2H), 6.66–7.60 (m, 23H); ¹³C NMR (100 MHz, CDCl₃) δ 53.9, 57.7, 59.0 (d, ¹*J*(P–C) = 65.1 Hz), 116.9 (d, ²*J*(P–C) = 5.5 Hz), 122.9, 123.2, 125.6 (d, *J*(P–C) = 7.3

Hz), 126.1, 126.9 (d, J(P-C) = 8.0 Hz), 127.2, 127.3, 127.4 (d, J(P-C) = 4.1 Hz), 127.5, 130.4, 130.6, 130.9, 131.5, 132.6, 132.7, 132.8, 132.9, 133.9, 139.3, 139.6, 141.4, 141.5, 141.7, 144.4; ³¹P NMR (162 MHz, CDCl₃) δ 32.8; LC/MS m/z 496 [M + 1]⁺. Anal. calcd for C₃₅H₂₇OP: C, 85.00; H, 5.50. Found: C, 85.12; H, 5.48.

Compound 70. In the reaction of allenylphosphonate **2** (0.32 g, 1.60 mmol) with anthracene (0.99 g, 5.58 mmol), self-dimerized product **70** (yield: 15%) was formed along with product **59**. The eluent used for compound **70** was ethyl acetate/hexane (4:1) mixture. Yield [**59** + **70**] quantitative by ³¹P NMR, 0.09 g (isolated, 15%, **70**); mp 258–260 °C; IR (KBr, cm⁻¹) 2969, 2930, 2886, 1632, 1468, 1372, 1262, 1057, 1005, 984; ¹H NMR (400 MHz, CDCl₃) δ 1.07 and 1.08 (2 s, 12H), 1.97 (d, ³*J*(P–H)= 14.4 Hz, 6H), 2.89 (s, 4H), 3.78 (dd→t, ³*J*(P–H) = ²*J*(H–H) ≈ 11.4 Hz, 4H), 4.16 (dd→t, ³*J*(P–H) = ²*J*(H–H) = 11.0 Hz, 4H); ¹³C NMR (100 MHz, CDCl₃) δ 18.0, 18.1, 21.6, 30.5 (d, ³*J*(P–C) = 5.0 Hz), 32.5 (d, ³*J*(P–C) = 5.8 Hz), 75.3₀, 75.3₃, 116.8 (d, ¹*J*(P–C) = 174.0 Hz), 155.2 (d, ²*J*(P–C) = 38.5 Hz); ³¹P NMR (162 MHz, CDCl₃) δ 15.2; LC/MS *m*/*z* 405 [M + 1]⁺. Anal. calcd for C₁₈H₃₀O₆P₂: C, 53.46, H; 7.48. Found: C, 53.51; H, 7.40.

X-Ray Data. X-ray data for compounds 24, 25.CH₂Cl₂, 31a, 33b.CHCl₃, 36a, 36b.H₂O, 44a, 46a.CH₂Cl₂, 46b, 47a, 52, 53, 55, 61, 64, 66 and 70 were collected on Bruker AXS SMART or OXFORD diffractometer using Mo– K_{α} (λ =0.71073 Å) radiation. The structures were solved and refined by standard methods.²⁷ CCDC numbers are CCDC 800084 - 800100.

Crystal Data. 24: C₁₆H₂₃O₇P, M = 358.31, Monoclinic, Space group P2(1)/c, a = 15.4896(13), b = 6.3827(5), c = 22.4035(15) Å, $\beta = 121.467(4)^{\circ}$, V = 1889.2(3) Å³, Z = 4, $\mu = 0.177$ mm⁻¹, data/ restraints/parameters: 4444/0/222, R indices ($I > 2\sigma(I)$): R1 = 0.0678, wR2 (all data) = 0.1473. CCDC no. 800084.

25: CH₂Cl₂: C₁₇H₂₅Cl₂O₇P, M = 443.24, Monoclinic, Space group P2(1)/c, a = 13.9539(13), b = 9.8610(9), c = 16.9007(16) Å, $\beta = 111.638(2)^{\circ}$, V = 2161.7(3) Å³, Z = 4, $\mu = 0.408$ mm⁻¹, data/restraints/parameters: 3801/0/250, R indices ($I > 2\sigma(I)$): R1 = 0.0853, wR2 (all data) = 0.1886. CCDC no. 800085.

31a: C₂₁H₂₅O₇P, \dot{M} = 420.38, Monoclinic, Space group P2/c, a = 16.4839(11), b = 6.6740(4), c = 22.516(2) Å, $\beta = 120.625(6)^{\circ}$, V = 2131.6(3) Å³, Z = 4, $\mu = 0.168$ mm⁻¹, data/restraints/ parameters: 3068/0/268, R indices ($I > 2\sigma(I)$): R1 = 0.0447, wR2 (all data) = 0.0991. CCDC no. 800086.

33b: CHCl₃: C₁₀₉H₁₂₅Cl₃O₄₈P₄, M = 2433.32, Monoclinic, Space group C2/c, a = 17.863(3), b = 24.4265(19), c = 16.784(2) Å, $\beta = 118.377(18)^{\circ}$, V = 6443.4(14) Å³, Z = 2, $\mu = 0.204$ mm⁻¹, data/restraints/parameters: 5613/0/376, R indices ($I > 2\sigma(I)$): R1 = 0.0807, wR2 (all data) = 0.2176. CCDC no. 800087.

36a: C₂₃H₂₇O₇P, M = 446.42, Monoclinic, Space group P2(1)/c, a = 9.7156(4), b = 12.7031(6), c = 20.6130(10) Å, $\beta = 112.620(4)^{\circ}$, V = 2348.32(19) Å³, Z = 4, $\mu = 0.157$ mm⁻¹, data/restraints/ parameters: 4117/0/284, R indices ($I > 2\sigma(I)$): R1 = 0.0595, wR2(all data) = 0.1789. CCDC no. 800088.

36b: H₂O: C₂₉H₃₅O₁₂P, M = 606.54, Monoclinic, Space group P2(1)/c, a = 14.9743(8), b = 10.9942(6), c = 18.6852(10) Å, $\beta = 91.7590(10)^{\circ}$, V = 3074.7(3) Å³, Z = 4, $\mu = 0.150$ mm⁻¹, data/restraints/parameters: 5398/0/392, R indices ($I > 2\sigma(I)$): R1 = 0.0470, wR2 (all data) = 0.1235. CCDC no. 800089.

44a: $C_{34}H_{31}O_4P$, M = 534.56, Monoclinic, Space group P2(1)/c, a = 11.7888(17), b = 14.997(2), c = 16.960(4) Å, $\beta = 112.545(16)^{\circ}$, V = 2769.3(8) Å³, $Z = 4, \mu = 0.137$ mm⁻¹, data/restraints/parameters: 4861/0/354, R indices ($I > 2\sigma(I)$): R1 = 0.0350, wR2 (all data) = 0.0857. CCDC no. 800090.

^{(27) (}a) Sheldrick, G. M., SADABS, Siemens Area Detector Absorption Correction; University of Göttingen: Germany, 1996. (b) Sheldrick, G. M., SHELX-97- A program for crystal structure solution and refinement; University of Göttingen: Germany, 1997. (c) Sheldrick, G. M., SHELXTL NT Crystal Structure Analysis Package, version 5.10; Bruker AXS, Analytical X-ray System: Madison, WI, 1999.

46a: CH₂Cl₂: C₃₆H₃₅Cl₂O₅P, M = 649.51, Monoclinic, Space group P2(1)/c, a=9.9415(2), b=27.0182(6), c=14.0924(4) Å, $\beta=124.847(2)^{\circ}$, V = 3106.47(13) Å³, Z = 4, $\mu = 0.304$ mm⁻¹, data/ restraints/parameters: 5461/0/400, R indices ($I > 2\sigma(I)$): R1 = 0.0684, wR2 (all data) = 0.1751. CCDC no. 800091.

46b: $C_{35}H_{33}O_5P$, M = 564.58, Monoclinic, Space group P2(1)/c, a = 10.3316(7), b = 16.5344(11), c = 17.8866(16) Å, $\beta = 108.912(7)^\circ$, V = 2890.6(4) Å³, $Z = 4, \mu = 0.138$ mm⁻¹, data/restraints/parameters: 5083/0/373, R indices ($I > 2\sigma(I)$): R1 = 0.0383, wR2 (all data) = 0.0906. CCDC no. 800092.

47a: C₂₆H₂₂O₃, M = 382.44, Triclinic, Space group $P\overline{1}$, a = 9.315(5), b = 10.467(6), c = 11.211(6) Å, $\alpha = 76.848(9)^{\circ}$, $\beta = 76.187(10)^{\circ}$, $\gamma = 75.850(10)^{\circ}$, V = 1012.5(10) Å³, Z = 2, $\mu = 0.081$ mm⁻¹, data/restraints/parameters: 3561/0/263, R indices ($I > 2\sigma(I)$): R1 = 0.0785, wR2 (all data) = 0.1640. CCDC no. 800093.

52: C₄₀H₃₅O₂P, M = 578.65, Triclinic, Space group $P\overline{1}$, a = 9.8726(6), b = 11.7485(7), c = 14.2263(9) Å, $\alpha = 94.0200(10)^{\circ}$, $\beta = 91.4210(10)^{\circ}$, $\gamma = 111.2630(10)^{\circ}$, V = 1531.73(16) Å³, Z = 2, $\mu = 0.125$ mm⁻¹, data/restraints/parameters: 5395/0/388, R indices ($I > 2\sigma(I)$): R1=0.0457, wR2 (all data)=0.1100. CCDC no. 800094.

53: $C_{34}H_{35}O_4P$, M = 538.59, Monoclinic, Space group P2(1)/c, a = 13.2152(16), b = 14.2689(15), c = 17.500(3) Å, $\beta = 121.267(10)^\circ$, V = 2820.6(7) Å³, $Z = 4, \mu = 0.135$ mm⁻¹, data/restraints/parameters: 4948/0/354, R indices ($I > 2\sigma(I)$): R1 = 0.0446, wR2 (all data) = 0.1052. CCDC no. 800095.

55: C₄₀H₃₉O₄P, M = 614.68, Monoclinic, Space group P2(1)/c, a = 15.8406(19), b = 14.0154(11), c = 19.0996(19) Å, $\beta = 108.257(12)^{\circ}$, V = 4026.9(7) Å³, Z = 4, $\mu = 0.102$ mm⁻¹, data/ restraints/parameters: 6919/0/408, R indices ($I > 2\sigma(I)$): R1 = 0.0807, wR2 (all data) = 0.2574. CCDC no. 800096. **61**: C₂₈H₂₇O₃P, M=442.47, Monoclinic, Space group P2(1)c, a=9.9536(8), b=16.2868(13), c=15.5212(10) Å, β =112.478(4)°, V=2325.0(3) Å³, Z=4, μ =0.146 mm⁻¹, data/restraints/ parameters: 4097/0/291, R indices ($I > 2\sigma(I)$): R1 = 0.0528, wR2 (all data) = 0.1219. CCDC no. 800097.

64: C₂₂H₂₃O₃P, M = 366.37, Orthorhombic, Space group *Pnma*, a = 23.597(9), b = 13.366(5), c = 6.132(3) Å, V = 1934.0(14) Å³, Z = 4, $\mu = 0.160$ mm⁻¹, data/restraints/parameters: 1782/0/133, R indices ($I > 2\sigma(I)$): R1 = 0.0679, wR2 (all data) = 0.1397. CCDC no. 800098.

66: C₂₉H₂₃OP, M = 418.44, Monoclinic, Space group Cc, a = 15.8800(15), b = 9.9538(9), c = 15.1330(14) Å, $\beta = 107.2870(10)^{\circ}$, V = 2284.0(4) Å³, Z = 4, $\mu = 0.138$ mm⁻¹, data/restraints/ parameters: 4351/0/281, R indices ($I > 2\sigma(I)$): R1 = 0.0381, wR2 (all data) = 0.0926. CCDC no. 800099.

70: $C_{18}H_{30}O_6P_2$, M = 404.36, Orthorhombic, Space group *Pbcn*, a=16.291(6), b=12.324(4), c=10.331(4) Å, V=2074.1(13) Å³, Z = 4, $\mu = 0.239$ mm⁻¹, data/restraints/parameters: 2536/0/121, R indices ($I > 2\sigma(I)$): R1 = 0.0463, wR2 (all data) = 0.1234. CCDC no. 800100.

Acknowledgment. We thank DST (New Delhi) for financial support and Single Crystal X-ray diffractometer facility and UGC (New Delhi) for equipment under UPE and CAS programs. K.V.S., R.K., M.C., and N.N.B.K. thank CSIR for fellowships.

Supporting Information Available: ORTEP drawings, CIF files, copies of ¹H and ¹³C NMR spectra. This material is available free of charge via the Internet at http://pubs.acs.org.